



Health Technology for a Better World



Tel.: 0756-3619693

Website: www.jafron.com

Email: ir@jafron.com

Address: 98 Keji 6th Road, Zhuhai National High-tech Industrial Development Zone, Zhuhai City, Guangdong, China

2025
Environmental, Social and Governance (ESG) Report

About this Report	01
Message from the Chairman	03
About Us	05

Annual Thematic Initiative:
 "Love Life, Love Life More" – 919 Uremia Awareness Day 23

Sustainable Development Governance

Governance Framework for Sustainable Development	25
Communications with Stakeholders	26
Management of Material Topics	27

Appendix

Indexes	108
Key Performance Form	109
Feedback Form	118

Driving Industry Transformation through Innovation and Collaboration 01

Innovation-Driven Development	31
Safety and Quality of Products and Services	42
Customer Service	48
Information Security and Data Protection	50
Responsible Supply Chain	53

Advancing Green Transformation to Enable Sustainable Healthcare 03

Response to Climate Change	71
Environmental Compliance Management	74
Resource Utilization	79
Ecosystem and Biodiversity Protection	84

Consolidating the Foundation for Sustainable Development through Steadfast Governance 02

Governance	61
Investor Relations Management and Shareholders' Rights and Interests	64
Compliant Operation and Risk Management	66
Business Ethics	68

Building a Harmonious Workplace through People-Oriented Development 04

Protection of Employees' Rights and Interests	87
Training and Development	93
Occupational Health and Safety	97
Social Contribution	104



About this Report

This is the second Environmental, Social and Governance (ESG) Report published by Jafron Biomedical Co., Ltd. ("Jafron", the "Company" or "we"). In the principles of objectivity, standardization, transparency, and comprehensiveness, the Report provides a detailed disclosure of the Company's practices and performance in environmental, social, and governance for the year 2025.

Reporting Scope

This report covers Jafron and its subsidiaries. Unless otherwise stated, the scope of this report is consistent with the scope of the Company's Annual Report.

Reporting Period

This report covers the period from January 1, 2025 to December 31, 2025 (the "Reporting Period"). To improve the comparability and completeness, some sections of this report may be appropriately referred to previous years or contains forward-looking statements.

Preparation Basis

- ◇ Shenzhen Stock Exchange Self-Regulatory Guidelines No. 17 for Companies Listed on Shenzhen Stock Exchange—Sustainability Report (For Trial Implementation)
- ◇ Shenzhen Stock Exchange Self-Regulatory Guidelines No. 3 for Listed Companies on the Shenzhen Stock Exchange - Preparation of Sustainability Reports
- ◇ Global Reporting Initiative Sustainability Reporting Standards (GRI Standards)
- ◇ China Enterprise Reform and Development Society Guide to Corporate Sustainability Reporting in China (CASS-ESG 6.0)
- ◇ Task Force on Climate-related Financial Disclosures (TCFD) Recommendations
- ◇ United Nations Sustainable Development Goals (SDGs)
- ◇ Sustainability Accounting Standards Board (SASB) Standards

Data Source

All information and data cited hereunder are sourced from Jafron's official documents, statistical reports and financial reports, as well as the sustainable development information collected, summarized and reviewed by all functional departments and business units of the Company.

The Company guarantees that this report doesn't contain any false records, misleading statements, or material omissions. Unless otherwise specified, all amounts in this report are expressed in RMB.

Appellation Description

Term	Definition
Jafron, the Company, we	Jafron Biomedical Co., Ltd.
Beijing Jafron	Beijing Jafron Medical Equipment Co Ltd.
Hubei Jafron	Hubei Jafron Biotechnology Co., Ltd.
Jianfu Pharmaceutical	Zhuhai Jianfu Pharmaceutical Co., Ltd.

Confirmation and Approval

This report was approved by the Board of Directors of the Company for publication on April 27, 2026. The Board pledges to exercise oversight over the contents of this report, ensuring its absence of any false records or misleading representations, and assuming responsibility for its truthfulness, accuracy and completeness.

Access to this Report

This report can be accessed and downloaded from the websites of the Company (<https://www.jafron.com>), the Shenzhen Stock Exchange (<http://www.szse.cn>) and Cninfo (<https://www.cninfo.com.cn>). This report is published in both Chinese and English. The English version is a translation of the Chinese version. For any discrepancy between the Chinese version and the English version, the Chinese version shall prevail.

Message from the Chairman

Dear shareholders, partners, and friends:

Hello, everyone!

On the occasion of the publication of Jafron's 2025 Environmental, Social and Governance (ESG) Report, I would like, on behalf of the Board of Directors, to extend my sincere gratitude to your ongoing support and trust in our company.

Creating Social Value, Driving Innovation-Led Development

Jafron remains firmly focused on the medical device sector, with the strategic objective of strengthening domestic production capabilities in advanced medical devices. We continue to drive industrial upgrading through innovation, fostering an integrated ecosystem that connects industry, academia, research institutions and clinical practice. This collaborative model is intended to accelerate the translation of proprietary technologies from laboratory research to clinical application, and from domestic deployment to global markets. In 2025, we further increased investment in research and development, intensified efforts to achieve breakthroughs in critical core technologies, and accelerated the commercialization of scientific achievements, delivering clinically differentiated solutions that address evolving patient needs. From the development of our first resin-based hemoperfusion cartridge to a comprehensive portfolio spanning six major areas—including treatment of kidney, liver and critical diseases—we will continue to expand the clinical boundaries of hemoabsorption technologies, enhancing the global reach and impact of "Created in China" innovations in advancing human health.

At present, China has approximately 120 million patients with chronic kidney disease and more than 3 million uremia patients worldwide. To help uremia patients progress from merely extending survival to rebuilding quality of life, we formally joined forces with Xinhuanet, the China Population Welfare Foundation and other partners to jointly advocate for the establishment of "919 Uremia Awareness Day" in 2025, encouraging broader social awareness and support for uremia patients. In collaboration with healthcare institutions, non-profit organizations and media partners, we implemented a series of public welfare initiatives, including health education, patient assistance and rehabilitation support programs. Through sustained engagement in philanthropic activities, we strive to extend care and support to underserved populations. We remain committed to a people-centric approach, continuously improving employee career development pathways and strengthening occupational health and safety management systems, while fostering an equitable, inclusive and dynamic workplace. In parallel, we uphold stringent quality and safety standards across the full product lifecycle—from research and development to manufacturing and post-market services—to safeguard user safety and health.

Embedding Environmental Responsibility, Pursuing Sustainable Growth

As a manufacturer of medical devices, we are fully aware of the environmental footprint associated with our production and operations. In 2025, we continued to advance our green manufacturing system by increasing investment in environmental protection infrastructure, optimizing process efficiency, and rigorously complying with applicable environmental laws and regulations. We further strengthened emissions control and promoted recycling of materials across our operations. Through these efforts, we are committed to building a resource-efficient and environmentally responsible enterprise, contributing to ecological conservation and the broader objective of building a beautiful China characterized by harmonious coexistence between man and nature.

Reinforcing Governance Foundations, Ensuring Compliance Excellence

Robust corporate governance is the lifeline of enterprises and underpins sustainable growth. In 2025, we further optimized our governance structure, enhanced the effectiveness of the Board of Directors and its specialized committees, and improved the rigor and transparency of our decision-making processes. We remained steadfast in our commitment to lawful and compliant operations, continuously strengthening internal controls and enterprise risk management systems. We also reinforced our culture of integrity and ethical conduct, promoting clean governance and responsible business practices throughout the organization. In December of the same year, the Private Enterprise Compliance Association of Guangdong Province was established. I was honored to be elected as its inaugural President, marking a high level of industry recognition for Jafron's achievements in compliance system development and reflecting our long-standing commitment to a compliance-first and prudent operating philosophy. In addition, we place strong emphasis on investor relations and are committed to disclosing true, accurate and complete information in a timely manner. We firmly believe that a strong governance foundation is essential to long-term, high-quality development.

Looking ahead, Jafron will remain steadfast in its mission of "Health Technology for a Better World". We will pursue technological innovation with a strong sense of responsibility, reinforce organizational resilience through robust governance, and contribute to sustainable development through environmentally responsible practices. Together with our stakeholders, we will continue to create long-term value and contribute to a healthier and more sustainable future.



Jafron Biomedical Co., Ltd.
Chairman
Dong Fan

About Us

Company Profile

Founded in 2002, Jafron Biomedical Co., Ltd. is a company listed on the ChiNext Market of the Shenzhen Stock Exchange (A-shares) (Stock Code: 300529), specializing in the R&D, manufacturing and sales of biomedical materials and advanced medical devices. The Company's core business focuses on hemopurification products and technologies. The Company ranks among the top Chinese listed companies in the medical device sector by market capitalization. It was recognized with prestigious awards such as the "Golden Bull Award for Best Investment Value" for 2017, 2018, 2019 and 2021 and "Top 50 ChiNext Listed Companies" for four consecutive years. In 2019, it was honored as the "Listed Company with Best Shareholder Return" and with China's Financial Annual Champion Award for ChiNext Market Listed "Competitive Enterprise". Jafron was also named one of the "Hurun China 100 Most Valuable Non-State-Controlled Healthcare Companies 2020". In the past three years alone, the Company has contributed nearly RMB 1.129 billion in taxes.

Jafron has earned numerous accolades, including: the Second Prize of the National Science & Technology Progress Award, the First Prize of Guangdong Science & Technology Progress Award, and Golden Bridge Award of China Technology Market Association; and it has been recognized as a Key High-Tech Enterprise under China's Torch Program, National Manufacturing Single-product Champion Demonstration Enterprise and National Technology Innovation Demonstration Enterprise. The Company has undertaken several major national and provincial science and technology projects, including: two National Key New Product Projects, three Projects under China's Torch Program, National Industrial Revitalization and Technological Transformation Projects, National Major Scientific and Technological Achievements Commercialization Projects, 12th Five-Year Plan Science and Technology Support Program, Open Bidding for Selecting the Best Candidates Program, Guangdong Strategic Emerging Industry Core Technology Research Program. It has received approvals to establish National Enterprise Technology Center, Academician Workstation, Postdoctoral Research Workstation, Provincial Engineering Research Center, Provincial Key Enterprise Laboratory, Provincial Engineering Technology Development Center and Provincial Postdoctoral Workstation. Jafron was among the first companies in China and the second in Guangdong Province to pass the medical device GMP inspection. Its products have received CE certification and ISO quality system certification. The Company has been rated as a Class A Medical Device Manufacturer in Guangdong's Quality Credit Evaluation for 12 consecutive years. In 2019, Jafron was recognized as a "Model Enterprise in the Pharmaceutical Industry" in celebration of the 70th Anniversary of the Founding of New China.

At the core of Jafron's portfolio are its proprietary, world-leading hemoperfusion cartridges, blood purification equipments, and its pioneering clinical medical technologies such as direct blood adsorption, DPMAS, combined artificial kidney and HA+CPB technologies, world-leading hemoperfusion devices, resin perfusion with whole blood, artificial liver, hybrid artificial kidney and HA+CPB technologies. Jafron's solutions are deployed across more than 6,000 hospitals in over 30 provinces throughout China, and are exported to over 90 countries worldwide, including Germany, the United Kingdom and Italy. These products and technologies play a critical role in managing severe and life-threatening conditions such as uremia, liver failure, poisoning and systemic lupus erythematosus. Jafron's solutions touch hundreds of thousands of patients each year.


Since the commissioning of its blood purification R&D and production facility (Jafron Science and Technology Park) in 2015, Jafron has expanded with three production bases in Zhuhai and new production and innovation centers in strategic regions including Beijing-Tianjin, Guangzhou-Shenzhen and Hubei Province. This geographic footprint supports a balanced industrial layout across South, Central and North China.

Looking forward, Jafron is advancing a holistic blood purification ecosystem that integrates blood purification equipments, consumables, pharmaceuticals, insurance solutions, chronic disease management and healthcare services. This full-spectrum blood purification value chain will support the Company's evolution into a diversified, globally recognized healthcare group and its vision to "Become a World-class High-tech Medical Technology Group".



Business Layout

Jafron's Global Footprint



Presence in **90+** countries
(including Europe, Asia, the Middle East,
Africa and South America)

Collaboration with **8,000+**
hospitals worldwide

Corporate Culture

Core Values

Innovation: Innovation is the primary engine of our growth. By embracing breakthroughs and taking on challenges, we sustain our industry leadership.

Dedication: We uphold a pragmatic and execution-focused work ethic. Through disciplined implementation and a results-oriented approach, we ensure consistent delivery of high-quality outcomes.

Advancing: Continuous improvement is our enduring pursuit. We are committed to ongoing capability enhancement, with today's highest standards becoming tomorrow's baseline.

Sharing: Creating shared value is the ultimate goal of our efforts. We are committed to sharing the benefits of our development with employees, shareholders, customers and the broader community.

Business Philosophy

Striver-Centered: Our employees are our most valuable asset. We are dedicated to fostering an enabling environment that supports professional growth, maximizes individual potential, and aligns personal development with organizational objectives.

Building Excellence through Expertise: We adhere to the principle of cultivating and leveraging highly skilled talent. By employing state-of-the-art production facilities, advanced manufacturing technologies and comprehensive inspection systems, we deliver high-quality products and maintain our industry-leading position.

Quality-Driven: This principle underpins our approach to entering the market with our products and services, and serves as the foundation and starting point of all that we offer.

Integrity in Service: Customer satisfaction is the ultimate objective of all our efforts.



Vision

Become a World-class High-tech Medical Technology Group

Corporate Spirit

Think Before You Act; Persevere Without Retreat

Mission

Health Technology for a Better World

Development Milestones

2005

- Introduced the "Jafron" trademark and established a proprietary brand



2004

- Launched flagship product HA130 Disposable Hemoperfusion Cartridge and promoted Combined Artificial Kidney Therapy nationwide



2002

- Completed ownership restructuring and embarked on entrepreneurial transformation



1989

- Established the company

2009

- Received the Second Prize of National Science & Technology Progress Award



2010

- Renamed "Zhuhai Jafron Biotechnology Co., Ltd."



2015

- Jafron Science and Technology Park headquarters completed and operational



2016

- Listed on the ChiNext Market of the Shenzhen Stock Exchange (A-shares)
- DPMAS included in the Artificial Liver Therapy Guidelines



2020

- Recognized as a "National Advanced Private Enterprise in the Fight Against COVID-19"
- Jafron products included in severe COVID-19 treatment guidelines across many countries

2019

- Hosted the inaugural Jafron International Summit on Hemoadsorption



2018

- Major results achieved in multicenter RCT study of HA130 Disposable Hemoperfusion Cartridge
- Renamed Jafron Biomedical Co., Ltd.



2021

- Honored as a "National Manufacturing Single-product Champion Demonstration Enterprise"
- Published the *Hemoperfusion in Maintenance Hemodialysis Patients and Blood Purification Standard Operating Procedures (2021 Edition)*



2022

- Zhuhai Jinding Industrial Park commenced production
- Recognized as a "National Technology Innovation Demonstration Enterprise", "National Enterprise Technology Center" and "National Model Enterprise for Harmonious Labor Relations"



2023

- Awarded the First Prize of Guangdong Science & Technology Progress Award
- Selected for the "Open Bidding for Selecting the Best Candidates" program; the only company in Guangdong to undertake development of medical-grade polyethersulfone materials
- Successfully hosted the 2nd International Hemoadsorption Summit



2025

- Customer Service Center recognized as "National March 8th Red-Banner Collective"
- Initiated the establishment of "919 Uremia Awareness Day", with cumulative contributions to public welfare initiatives totaling RMB 20 million.




Proprietary Products

Since launching its first HA series hemoperfusion cartridge in 2002, Jafron has dedicated over 24 years to advancing adsorption technology. It currently holds 29 medical device registration certificates, including 25 Class III certificates, spanning across the industrial chain of both consumables and medical devices in the blood purification field.

Product Category	Clinical Applications	Product Models
Hemoperfusion Cartridges	Kidney Diseases	<ul style="list-style-type: none"> ○ HA Series Disposable Hemoperfusion Cartridges ○ KHA Series Disposable Hemoperfusion Cartridges ○ pHA Series Disposable Hemoperfusion Cartridges
	Liver Diseases	<ul style="list-style-type: none"> ○ HA330-II and HA60 Disposable Hemoperfusion Cartridges ○ BS330 and BS80 Disposable Plasma Bilirubin Adsorption Columns
	Critical Diseases	<ul style="list-style-type: none"> ○ HA330 Disposable Hemoperfusion Cartridges for acute poisoning interventions ○ HA380 Disposable Hemoperfusion Cartridges which is widely used in cardiac surgery, severe acute pancreatitis (SAP), multiple organ dysfunction syndrome (MODS), acute respiratory distress syndrome (ARDS), sepsis/septic shock, severe burns, etc. ○ CA330 Cytokine Adsorption Column that is specifically designed to reduce cytokine levels in septic patients
	Immunology	<ul style="list-style-type: none"> ○ HA280 Disposable Hemoperfusion Cartridges indicated for autoimmune diseases such as anaphylactoid purpura, psoriasis and rheumatoid arthritis ○ DNA230 Immunosorbent Column indicated for systemic lupus erythematosus



Product Category	Clinical Applications	Product Models
Dialysis Products	Acute and chronic renal failure	<ul style="list-style-type: none"> ○ Comprehensive range of hemodialysis concentrates and powders, including high-potassium formulas, citrate-based solutions/powders, glucose-containing solutions, and solutions with varying calcium ion concentrations ○ 13 specifications of High-flux Hemodialyzers ○ 11 specifications of Low-flux Hemodialyzers




Product Category	Clinical Applications	Product Models
Blood Purification Equipment	Medical devices that provide extracorporeal circulation drive and safety monitoring for clinical blood purification	<ul style="list-style-type: none"> ○ DX-10 Blood Purification Machine ○ JF-800A Hemoperfusion Machine ○ Future F20 Hemoadsorption Equipment




Clinical Applications			
Poisoning <ul style="list-style-type: none"> Pesticide poisoning Drug poisoning 	Uremia <ul style="list-style-type: none"> Treatment and prevention of dialysis complications, including: Hypotension, arrhythmia, muscle cramp, hypoxemia, pruritus, air embolism, hemolysis, sleep disorders, subdural hematoma 	Liver Diseases <ul style="list-style-type: none"> Liver failure Hepatic encephalopathy Hyperbilirubinemia Cholestatic liver disease Perioperative treatment in liver transplantation 	Critical Care <ul style="list-style-type: none"> Severe acute pancreatitis (SAP) Cardiac surgery Severe burns Trauma Sepsis/septic shock Acute respiratory distress syndrome (ARDS) Multiple organ dysfunction syndrome (MODS)
Estimated Market Potential	RMB 200+ billion	RMB 100+ billion	RMB 200+ billion

Proprietary Technologies


Direct Blood Adsorption: This blood purification therapy involves drawing a patient's blood into an external circulation system, where endogenous and exogenous metabolic waste, toxins and residual drugs are removed through adsorption by specialized resins within the hemoperfusion cartridge. Leveraging its expertise in encapsulation technology, carrier preparation, ligand engineering and medical-grade purification processes, the Company has developed adsorbents with outstanding biocompatibility, clinical-grade safety and specific adsorption performance, enabling safe direct contact with human blood.




Combined Artificial Kidney Therapy: This therapy combines hemoperfusion with hemodialysis to achieve broad-spectrum removal of uremic toxins. By integrating the complementary mechanisms of perfusion and dialysis, the system significantly enhances the clearance of medium to large molecules and protein-bound uremic toxins—offering a more effective solution than conventional blood purification methods.



Double Plasma Molecular Absorb System (DPMAS): DPMAS is an innovative artificial liver therapy pioneered by Jafron. It combines two proprietary products—an ion-exchange resin-based bilirubin adsorption column (BS330) and a neutral macroporous resin-based hemoperfusion cartridge (HA330-II)—to create a synergistic blood purification effect. DPMAS can be used either independently or in combination with plasma exchange and other therapies. It enables rapid symptom relief, increases treatment success rates and improves prognosis outcomes. It is indicated for liver failure, hepatopulmonary syndrome and multiple organ dysfunction syndrome (MODS), regardless of etiology.



HA+CPB: This technique involves incorporating the HA380 Disposable Hemoperfusion Cartridge into a cardiopulmonary bypass (CPB) circuit. Blood is diverted from a side branch of the oxygenator through the cartridge and then returned to the reservoir. During this process, synthetic resins effectively adsorb inflammatory mediators generated during CPB treatment, helping to mitigate cytokine storm cascades. This significantly reduces systemic inflammatory responses during extracorporeal circulation in adult patients, stabilizes organ function and improves overall prognosis. The technology has been widely adopted in cardiac surgery and other treatment scenarios.



Production Capacity Layout

The Zhuhai region serves as Jafron's corporate headquarters and principal hub for research and development, manufacturing and operational management. Jafron's self-funded blood purification R&D and production facility (Jafron Science and Technology Park South Campus) was completed and commenced operations in 2015, covering 32,000 square meters of land and a total floor area of 65,000 square meters. In 2021, the Jafron Science and Technology Park North Campus was completed and began production, occupying over 18,000 square meters of land and a total floor area of approximately 55,000 square meters. Connected to the South Campus via the "Jafron Bridge", the unified complex now stands as one of the world's largest and most advanced R&D and manufacturing centers for hemodialysis and hemoperfusion products and solutions.

In addition, the Jinding Industrial Park in Zhuhai, developed by Jafron, spans nearly 90,000 square meters. The Phase I work, covering approximately 75,000 square meters of total floor area, was completed and operational in 2022. The Phase II work is planned to add another 100,000 square meters of construction area. Once fully completed, the park will focus on the production of hemoperfusion cartridges, nano-grade medical materials, hemodialyzers and plasma separators, among others. It is poised to become one of the world's largest and most technologically advanced production bases for blood purification devices and consumables.

Meanwhile, the Jianshu Core Hemopurification Material R&D and Production Base, located in Zhuhai Gaolan Port Economic Zone and positioned as a technology-driven manufacturing base, is owned and operated by Jafron's subsidiary Zhuhai Jianshu New Materials Technology Co., Ltd. The Phase I construction of the biomaterials project was structurally completed in August 2022 and will soon incorporate fully automated, high-efficiency resin production lines. Upon completion, it will become a leading raw materials production base with top-tier automation and process capabilities in the fine chemical industry. In the pharmaceuticals field, Jianfu Pharmaceutical, a subsidiary with its 10% equity owned by Jafron and controlled by the Company's ultimate beneficial owner, is developing a pharmaceuticals R&D and production base. Phase I of this project, spanning approximately 130 mu (about 86,700 square meters) and involving a planned investment of around RMB 1.5 billion, was structurally completed in 2023, aiming to build a first-class pharmaceutical research and production base in the near future.



Jafron Science and Technology Park South Campus

Jafron Science and Technology Park North Campus


Jinding Industrial Park



Jianshu New Materials Production Base (under development)

Jianfu Pharmaceutical (equity affiliate, under development)

Hubei Regional Footprint: In December 2021, the Hubei Jafron Industrial Park was completed and commenced operations, undertaking multiple projects across Jafron's integrated blood purification value chain. Positioned as a leading domestic manufacturing base for blood purification consumables and equipment, the park is expected to deliver more premium, original Chinese blood purification products to markets across China and globally, serving as an important strategic pillar for Jafron in Central China.



Hubei Production Base

Beijing/Tianjin Regional Footprint: In December 2013, Jafron acquired Beijing Jafron Medical Equipment Co., Ltd., which primarily engages in the production and sale of the DX-10 Blood Purification Machine and related products. In 2017, Jafron acquired Tianjin Standard Biological Preparation Co., Ltd., which facilitated the formation of the Tianjin R&D and production base for blood purification products. This base focuses on the research, development, production and sales of blood purification products such as Hemodialysis Powder and Concentrate, effectively serving demand across the North China market.



Tianjin Production Base

Through these strategic deployments, Jafron has established an industrial footprint anchored by its Zhuhai, Hubei and Beijing/Tianjin bases, creating a regional network spanning South China, Central China and North China. This layout provides solid manufacturing capacity to support the Company's continued focus on the blood purification sector and its pursuit of high-quality development.



Honors in 2025


Honors

- Second Prize of Guangdong Science and Technology Progress Award 2024
People's Government of Guangdong Province
- National March 8th Red-Banner Collective
All-China Women's Federation
- Guangdong Guangcai Program Contribution Award
CPC Guangdong Provincial Committee; People's Government of Guangdong Province
- Commendation under the "Hundred Associations & Ten Thousand Enterprises" Initiative
Guangdong Federation of Industry & Commerce
- Honorary Certificate for Contributions to the High-Quality Development Project for Hundreds of Counties, Thousands of Towns and Tens of Thousands of Villages
United Front Work Department of the CPC Guangdong Provincial Committee
- Outstanding Contribution Award of the Navigator Program
China Medical Tribune
- Top 100 Innovative Enterprises in Zhuhai 2024 – Innovation Strength Index
Zhuhai Municipal Bureau of Science & Technology Innovation
- Top 100 Innovative Enterprises in Zhuhai 2024 – Economic Contribution Index
Zhuhai Municipal Bureau of Science & Technology Innovation
- Urban Industrial Development Partner
Management Committee of Zhuhai Hi-tech Industrial Development Area
- 2024 Benchmark Enterprise for High-Quality Development of Zhuhai's Medical Device Industry
Zhuhai Association for Medical Devices Industry
- 2025 Philanthropic Enterprise Supporting the Development of Zhuhai's Medical Device Industry
Zhuhai Association for Medical Devices Industry
- "Shiji" Specialization and Excellence Leadership Gold Award
Market Supervision Administration of Zhuhai National High-Tech Industrial Development Zone
- Green Development Benchmark Enterprise in Zhuhai National High-Tech Industrial Development Zone
Greening Committee Office of Zhuhai National High-Tech Industrial Development Zone
- Humanitarian Commitment Award
Zhuhai Red Cross Society
- Women's Initiative for Beautiful Courtyards Supporting the High-Quality Development Project for Hundreds of Counties, Thousands of Towns and Tens of Thousands of Villages
Zhuhai Women's Federation
- Golden Bull Award (2024 Golden Disclosure Award)
China Securities Journal
- SSE Eagle · Gold Quality 2025 ESG Award
Shanghai Securities News
- Tianma Award for Investors Relation Management and Shareholders Returns
Securities Times




Product Honors


Awarding Authority
Zhuhai Municipal Bureau of Science & Technology Innovation




2025 Zhuhai Innovative Product Certificate (CRRT Tubing Sets – DX-CH, DX-DF, DX-DP, AT-01, AT-03)




2025 Zhuhai Innovative Product Certificate (Disposable Plasma Separators – JMPS-05, JMPS-07)



2025 Zhuhai Innovative Product Certificate (Disposable Hemoperfusion Cartridges – JMPS-05, Ha430)



2025 Zhuhai Innovative Product Certificate (Disposable Hemoperfusion Cartridges – JMPS-05, pH130)



2025 Zhuhai Innovative Product Certificate (Disposable Hemodialyzer – BT-101-01-1, ET-3, ET-5, BT-101-02)

Performance Highlights in 2025

Economic Performance



Operating Revenue
RMB **2,011.818** million

Net Profit Attributable to Owners of the Parent Company
RMB **532.8213** million

Total Assets
RMB **5,408.954** million

Earnings per Share
RMB **0.69** /share

Total Taxes
RMB **401.7469** million

Environmental Performance



Total Environmental Investment
RMB **2.2880** million

Training on Environmental Protection
10 times

Waste Disposal Compliance Rate
100%

Total GHG Emissions
13,974.11 tCO₂e

Waste Recycling Rate
27.66%

Social Performance



Signing Rate of Employment Contract
100%

Coverage Rate of Social Insurance
100%

Coverage Rate of Health Checkups among Employees
100%

Coverage Rate of Safety Training
100%

Work Safety Accidents
0 times

Charitable Contributions
RMB **44.5931** million

Investment in R&D
RMB **198.4453** million

First Pass Yield
100%



Annual Thematic Initiative / "Love Life, Love Life More" – 919 Uremia Awareness Day

Responsibility in Action, Mission in Focus

On September 19, 2025, Jafron, in collaboration with Xinhuanet, successfully convened the public launch event for "919 Uremia Awareness Day" at MedCreatives in Beijing. At the event, the Company formally proposed the establishment of September 19 as an annual "Uremia Awareness Day", under the theme "Love Life, Love Life More". The national launch event brought together stakeholders from healthcare institutions, charitable organizations, media outlets and patient representatives, jointly focusing on the living conditions and long-term outlook of more than 3 million uremia patients worldwide. The Company consistently embeds its mission of "Health Technology for a Better World" into its corporate development. Leveraging more than two decades of expertise in hemoperfusion technologies, we are committed to enabling the transition for patients from survival to a life of improved quality. Through continuous innovation, we strive to enhance the accessibility of advanced medical technologies and expand equitable access to high-quality care. The successful launch of this initiative represents a milestone in the Company's efforts to advance healthcare accessibility. By leveraging corporate capabilities, we are building a broader platform for social engagement and patient support, further strengthening public awareness of the concept of "Love Life, Love Life More".



Health Education and Awareness: Spreading Hope

On the inaugural 919 Uremia Awareness Day, Jafron partnered with mass media, medical institutions and public welfare organizations to launch the "Three-One" initiative: a nationwide Awareness Day kickoff event, a series of health education activities, and a package of kidney patient care programs. Bridging scientific knowledge with real-world patient needs is a key pillar of Jafron's "Three-One Initiative". In connection with "919 Uremia Awareness Day", the Company collaborated with leading medical institutions and clinical experts to launch a series of health education and awareness programs aimed at improving public understanding of chronic kidney disease. During the "Navigator Program" segment at the second half of the event, experts including Professor Ding Xiaoqiang of Zhongshan Hospital, Fudan University, and Professor Lin Hongli of the Institute of Nephrology, Dalian Medical University, delivered keynote presentations and participated in panel discussions on topics such as standardized hemoperfusion therapy and the management of uremia-related complications. The discussions provided clear, clinically grounded insights into how modern blood purification technologies can support patients in achieving a higher quality of life. In parallel, through digital platforms, patient education materials and community outreach initiatives, we disseminated knowledge on combined artificial kidney therapies, updates on medical insurance policies and daily care guidance to patients and their families, supporting more informed disease management and improved quality of life. These initiatives not only strengthened patient confidence in treatment but also supported the standardized adoption of hemoperfusion technologies, contributing to the advancement of the "Healthy China 2030" chronic disease prevention and control objectives.



Care for Kidney Patients: Advancing Together with Compassion

From commitment to execution, Jafron has translated the theme "Love Life, Love Life More" into a series of structured patient support programs for individuals with kidney disease. In collaboration with the China Population Welfare Foundation and other organizations, Jafron launched three public welfare programs, with total cash and in-kind contributions amounting to RMB 20 million, delivering tangible support to patients with uremia across China.

As of January 31, 2026, following the launch in September 2025, these programs have achieved meaningful progress:

The "Guard Heart & Kidney – Jafron Care Public Welfare Program" focuses on patients with uremia complicated by hypertension or cardiovascular disease. The program is designed to provide up to 10 sessions of combined artificial kidney therapy per patient, along with living subsidies, covering a total of 1,919 beneficiaries. To date, 399 assistance applications have been received, and 862 treatment sessions have been delivered to eligible patients under the program.

The "Guard the Lifeline – Jafron Warm Sun Public Welfare Initiative" has donated YH01 infrared therapy apparatus to 16 hospitals nationwide, enabling patients to access high-quality care closer to home and effectively improving the management experience of arteriovenous fistula care.

The "Guard the Lifeline – Jafron Red-Blue Tourniquet China Tour" mobilizes a network of healthcare volunteers to extend patient support at scale. To date, 211 medical volunteers have participated in the program, 1,632 valid patient applications have been received, and 701 pairs of red-blue tourniquets have been distributed, extending care and support to a wider patient population.

Through these initiatives, we continue to fulfill our corporate social responsibility commitments, ensuring that every patient with kidney disease feels dignity, respect and societal support. We are dedicated to helping patients transition from survival to a life of improved quality, enabling them to shape their own meaningful journey of life.



Sustainable Development Governance

Jafron has remained steadfast in its mission of "Health Technology for a Better World". We are committed to delivering safer and more sustainable healthcare solutions to people around the world. We embed ESG principles into the very fabric of our corporate strategy and day-to-day operations, supported by a continuously evolving sustainability management system. Meanwhile, we continue to strengthen engagement and communication with stakeholders, striving to deliver both economic and social values and promote harmonious coexistence of Jafron with society and the environment.

Governance Framework for Sustainable Development

To further strengthen corporate governance, regulate ESG management and improve ESG performance, Jafron approved the reconstitution of the Strategy Committee into the Strategy and ESG Committee during the reporting period. This enhancement reinforces the Board's oversight of and engagement in ESG-related matters and supports the structured implementation of the Company's sustainability strategy. The Board of Directors, as the highest decision-making body, assumes ultimate responsibility for ESG oversight, including the review and approval of the annual ESG report. The Strategy and ESG Committee is responsible for monitoring ESG-related regulatory developments and policy trends, formulating ESG strategies, implementation plans and objectives, evaluating ESG performance, and overseeing the preparation of ESG reports, while providing professional recommendations to the Board. An ESG Working Group has also been established, with dedicated personnel assigned to follow up on ESG initiatives. The Group is responsible for facilitating cross-departmental collaboration, driving the execution of ESG initiatives, and supporting the formulation, monitoring and risk management of the Company's sustainability objectives.

Looking ahead, we will continue to refine our sustainability governance structure and institutional framework, further enhancing governance effectiveness.

In parallel, Jafron has systematically developed an ESG indicator system, incorporating quantitative metrics to evaluate the effectiveness of ESG management strategies. A performance-linked supervision and assessment mechanism is being progressively established. During the reporting period, we issued a safety and environmental protection supervision and assessment program, explicitly linking key performance indicators—such as work safety, occupational health and environmental protection—to performance evaluation. We also implemented a structured monitoring, assessment and incentive mechanism to promote proactive engagement in safety and environmental management across all functional departments and operational sites.

Jafron also places strong emphasis on ESG awareness and capability building. Dedicated ESG training programs are regularly conducted, covering regulatory context, policy interpretation, emerging trends and leading industry practices. These initiatives enhance organization-wide understanding and execution capabilities, providing both talent support and institutional assurance for the achievement of sustainability objectives, while continuously strengthening overall governance standards.

Jafron Conducted Training on ESG Policy and Institutional Framework in May 2025

Case 



Communications with Stakeholders

Jafron places strong emphasis on engagement with key stakeholders, including shareholders, employees, suppliers and partners. By establishing regular, multi-channel communication mechanisms, we actively solicit and listen to stakeholder expectations and concerns and integrate these insights into our strategy and day-to-day operations.


Stakeholders	Expectations and Demands	Communication and Response
 Shareholders and Investors	Steady and compliant operation Transparent information disclosure Stable dividend returns	<ul style="list-style-type: none"> ○ Improve Corporate Governance Framework ○ Guarantee timely and accurate disclosures ○ Strengthen investor relations management ○ Enhance profitability and dividend payout capabilities ○ Protect long-term value for shareholders
 Employees	Protection of legal rights and interests Career development space Occupational health and safety	<ul style="list-style-type: none"> ○ Improve the compensation, benefits, and incentive system ○ Establish structured employee training and career progression pathways ○ Strengthen occupational health and safety management ○ Conduct employee care initiatives
 Customers	High-Quality and safe products Sound after-sales services Privacy information protection	<ul style="list-style-type: none"> ○ Increase R&D Investment ○ Strictly control product quality and safety ○ Optimize after-sales service processes ○ Protect data security and privacy
 Suppliers and Partners	Win-win cooperation Integrity-based operations Industry exchange	<ul style="list-style-type: none"> ○ Strengthen communication with suppliers ○ Implement transparent procurement ○ Establish strategic Cooperation
 Government or Regulator	Compliant operation Lawful tax payment Environmental compliance Rural revitalization	<ul style="list-style-type: none"> ○ Strictly comply with laws and regulations ○ Lawfully fulfill tax obligations ○ Enhance environmental compliance management capabilities ○ Align with rural revitalization policies
 Social Organizations or NGOs	Contribution to community development Support for vulnerable groups Fulfillment of social responsibilities Health education Adherence to science and technology ethics	<ul style="list-style-type: none"> ○ Strengthen community engagement ○ Participate in volunteer Services ○ Make public Welfare Donations ○ Conduct health education

Management of Material Topics

In accordance with the assessment methods stated in the domestic and international disclosure standards such as the Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 17 - Sustainability Report (for Trial Implementation), the International Financial Reporting Sustainability Disclosure Standards No. 1 - General Requirements for Disclosure of Sustainability (IFRS S1), and the GRI Standards, the Company introduces the analysis perspective of impact materiality and financial materiality to identify and assess material topics in the following steps:



Analysi of Double Materiality



Dimension	Topic	Statement of Materiality	Dimension	Topic	Statement of Materiality
Environment	Response to Climate Change	Double Materiality	Social	Innovation-driven Development	Double Materiality
	Environmental Compliance Management	Impact Materiality		Safety and Quality of Products and Services	Double Materiality
	Waste Disposal	Impact Materiality		Data Security and Privacy Protection	Impact Materiality
	Pollutant Emissions	Impact Materiality		Protection of Employees' Legal Rights and Interests	Impact Materiality
	Water Resource Utilization	Impact Materiality		Employee Training and Development	Impact Materiality
	Energy Utilization	Impact Materiality		Occupational Health and Safety	Impact Materiality
	Circular Economy	Impact Materiality		Science and Technology Ethics	General Materiality
	Ecosystem and Biodiversity Protection	General Materiality		Access to Healthcare	Impact Materiality
Governance	Anti-Commercial Bribery and Anti-Corruption	Impact Materiality	Supply Chain Security	Financial Materiality	
	Anti-Unfair Competition	General Materiality	Social Contribution	General Materiality	
	Due Diligence	General Materiality	Rural Revitalization	General Materiality	
	Communications with Stakeholders	General Materiality			


Driving Industry Transformation through Innovation and Collaboration

Jafron continues to accelerate technology commercialization and product iteration, promoting the large-scale adoption of innovative solutions in clinical settings. These efforts contribute to improving the quality of care and enhancing service accessibility in the blood purification field in China. By establishing a robust quality management system spanning the full value chain—from research and development, manufacturing and distribution to after-sales service—the Company promotes coordinated development across upstream and downstream partners, supporting the integration of regional economic development with the healthcare industry. We remain committed to innovation-driven industrial upgrading and actively contribute to industry standardization through technical leadership. Through ongoing participation in academic exchange and technology dissemination, we support the development of an open, collaborative and sustainable healthcare ecosystem.

ESG Material Topics Covered in this Chapter

- Innovation-driven Development
- Safety and Quality of Products and Services
- Science and Technology Ethics
- Access to Healthcare
- Supply Chain Security
- Data Security and Privacy Protection
- Due Diligence

SDGs Responded in this Chapter



01

Innovation-Driven Development

Jafron consistently positions scientific research and technological innovation at the core of its growth strategy. We are committed to building a synergistic industry value chain for blood purification equipment, integrating proprietary blood purification equipment, chronic disease management and medical services. We continue to strengthen our R&D management system, maintain sustained investment in innovation, and enhance the development of talent and innovation platforms to ensure that our technologies remain at the forefront of the industry. At the same time, we continuously optimize our product portfolio. In addition, we actively advance research collaboration and participate in academic exchange, fostering technological innovation and facilitating knowledge sharing, thereby contributing to the advancement of global healthcare.

Governance

With innovation as a core strategic priority, Jafron has established a systematic, end-to-end governance framework to ensure the efficient operation of its R&D system and the standardization of innovation processes.

At the policy level, we've formulated a series of core management systems, including the *End-to-End Process and Role Descriptions for New Product Development*, the *R&D Project Initiation Management Regulations*, and the *R&D Project Closure Management Regulations*, clearly defining process standards and accountability across all stages of innovation. At the organizational level, we've established a well-structured governance framework, with overall leadership provided by the President and coordinated by designated management personnel. This framework integrates specialized functions such as the Evaluation and Testing Center and the R&D Management Center, supported by professional roles including materials experts and human resources specialists. Together, these elements form a comprehensive "decision-making, coordination, execution and support" structure, ensuring the efficient allocation of innovation resources, strengthening cross-functional collaboration, and continuously enhancing overall innovation performance.

Innovation and R&D Platform

Jafron has established an integrated R&D platform for both consumables and medical devices, with the Science Building and the Shenzhen R&D Center Experimental Area serving as core hubs. Together, these facilities support a comprehensive R&D and testing system spanning the full spectrum of blood purification technologies. The Science Building comprises three dedicated centers—Polymeric Adsorbent Research Center, Product Technology R&D Center and Clinical Application Research Center—alongside a CNAS-accredited testing laboratory. The platform focuses on the development of core materials for polymeric adsorbents, cross-disciplinary product design, clinical scenario simulation, and end-to-end testing capabilities. It has enabled the development of multiple pioneering testing methodologies. Leveraging innovation platforms such as the Academician Workstation and Postdoctoral Research Workstation, the Company actively undertakes key technology R&D projects at all levels. The Shenzhen R&D Center Experimental Area is equipped with high-precision analytical and testing instruments, providing comprehensive validation capabilities for medical research and ensuring the quality and reliability of devices.



CNAS Laboratory Accreditation Certificate

Supported by strong independent R&D capabilities, Jafron has established multiple high-level research platforms, including a National Enterprise Technology Center, an Academician Workstation, a Postdoctoral Research Workstation, and a Provincial Engineering Research Center. We've undertaken numerous national and provincial key research projects.


Innovation Capability Certification

Specialized and Sophisticated Enterprise Certificate 1 pcs	National High-tech Enterprise Certificate 3 pcs	National Enterprise Technology Center Certificate 1 pcs
--	---	---



R&D Process

Jafron has implemented a standardized and end-to-end new product development process, guided by market demand and covering stages including project planning and initiation, design and development, technology transfer and validation, and regulatory registration. From requirement analysis and project approval to product design and prototyping, and further through registration testing, clinical evaluation and regulatory submission, each phase is governed by rigorous procedures and internal controls. Cross-functional collaboration is embedded throughout the R&D process, ensuring that products are compliant, safe and efficiently commercialized, while providing sustained support for high-quality product delivery and continuous innovation.



Innovation Talent Development

Jafron places strong emphasis on internal talent development and is committed to cultivating a highly skilled and innovation-driven R&D workforce, recognizing talent as a critical enabler of technological breakthroughs and the translation of research achievements into practical applications. Through a combination of internal and external training programs, professional development initiatives and knowledge-sharing mechanisms, we continuously expand the knowledge base of our R&D personnel and enhance their technical expertise and professional capabilities. At the same time, we deploy targeted training resources aligned with operational needs, further strengthening the overall competencies of our R&D teams and building a solid talent foundation to support sustained innovation and high-quality growth.

During the Reporting Period, the R&D team consists of **405** members, accounting for **17.60%** of the total workforce.

TRIZ Innovation Methodology Training

Case

In October 2025, Jafron conducted a dedicated training program focused on addressing innovation challenges. The program covered key methodologies and tools, including reverse thinking techniques, the Hetian's Twelve Ways, the Nine-Windows Technique, the Goldfish Method, and the TRIZ Contradiction Matrix. Using case studies such as "thin glass processing" and the "optimization of sterilization process validation equipment", the training provided a systematic walkthrough of the 15-step approach to applying the TRIZ Contradiction Matrix in solving technical challenges. The training effectively strengthened the innovative thinking capabilities and practical tool application skills of R&D personnel, further reinforcing the talent foundation for technological innovation and high-quality development.



Strategy

Jafron continuously monitors key factors, including national policy developments, competitive dynamics and technological advancements. Through systematic analysis of industry trends, we proactively identify risks and opportunities associated with innovation-driven growth and formulate targeted response strategies to effectively mitigate risks and capture emerging opportunities.

Risk Type	Description of Risk	Impact Duration	Potential Financial Impact	Countermeasures
Policy Risk	The medical device sector is subject to stringent government regulation. The Company must closely monitor changes in policies such as the <i>Regulations on the Supervision and Administration of Medical Devices</i> to ensure legal compliance. Failure to do so could result in penalties, lawsuits or other legal consequences.	Short and medium term	Increase of operational cost	<ul style="list-style-type: none"> ○ Closely monitor and study national and local policy and regulatory changes. ○ Timely adjust business strategies in response to market rule changes and regulatory updates induced by healthcare system reforms. ○ Continue to promote academic exchange and collaboration, adhere to a clinical evidence-based approach, and maintain strict compliance with regulatory requirements. ○ Strengthen ongoing compliance training to enhance the Company's ability to respond to risks associated with industry policy changes.
Technology Update and Iteration Risks	As R&D investment increases across the industry, new technologies and innovative products are likely to emerge in the near future. If the Company fails to keep pace with industry advancements or update its existing products in time, it may face adverse business impacts.	Medium term	Decrease in operating revenue	<ul style="list-style-type: none"> ○ Prioritize the development of a robust R&D system, enhance forward-looking strategic planning in technology innovation, and increase investment in new product development aligned with market demand. ○ Speed up the technical upgrade and optimization of existing products. ○ Strengthen IP protection to prevent leaks and infringement.
Industrial Competition Risk	With the rapid growth of the domestic hemoperfusion industry, expansion of existing enterprises and the entry of new players, competition is intensifying across the industry. Without continuous innovation in technology and product offerings, the Company may face a decline in market competitiveness.	Medium to long term	Market share and revenue loss	<ul style="list-style-type: none"> ○ Continue to focus on principal businesses, persist in technological innovation, actively expand product portfolios, and drive technological transformation of products alongside the upgrade of their applications. ○ Consistently enhance automation levels in production processes and IT-enabled management capabilities, introduce Hemoperfusion Cartridge Manufacturing 4.0, and continuously strengthen integrated smart manufacturing capabilities.

Opportunity Type	Description of Opportunity	Impact Duration	Potential Financial Impact
Industrial upgrading and transformation	Technological innovation is a key driver of industrial upgrading. By introducing new technologies, processes and management approaches, the Company can help drive the industry towards higher-end and smarter development.	Medium to long term	Reduced production costs and improved production efficiency
Technological innovation and market leadership	Persistent R&D efforts and breakthroughs in core technologies, along with continuous development of new products, can help the Company significantly enhance its competitive strength, secure market leadership and garner substantial profit returns.	Long term	Increase in operating income

Note: Impact Duration: refers to the different periods when different climate-related risks and opportunities will affect the Company. The Company categorizes the impact duration into short term (0-1 year), medium term (1-5 years), and long term (over 5 years).

Impact, Risk, and Opportunity Management

Jafron places strong emphasis on the management of innovation-related risks and opportunities. We've established a comprehensive risk and opportunity assessment framework to enable ongoing monitoring of key risk factors, including regulatory compliance, technology iteration and market competition. Through dynamic identification and evaluation of internal and external risk factors, we implement proactive mitigation measures to ensure resilient and effective risk management.

To address uncertainties inherent in the R&D process, Jafron has implemented the *Regulations on R&D Review Management*, which clearly define responsibilities and procedural requirements for R&D review activities. This framework establishes a full lifecycle management mechanism—covering risk identification, assessment, monitoring and control—ensuring that R&D risks are systematically managed and mitigated.

Metrics and Targets

In alignment with its medium- to long-term strategic objectives and the development approach of "products in market, products in reserve and products under development", the Company has formulated a five-year product development plan. This plan defines strategic technology directions, innovation objectives, the R&D system and capability development goals. Focusing on key and common technologies in the field of blood purification, we continue to advance core technology development and innovation, enhancing the competitiveness of our flagship products and supporting high-quality industry advancement.

R&D Goals	Achievements in 2025
Develop new technologies, materials and products to refine the blood purification industry chain and enhance core competitiveness.	<p>1. Strengthened the product portfolio across the blood purification value chain</p> <ul style="list-style-type: none"> ○ Obtained a Class II medical device registration certificate for disposable waste liquid bags; ○ Obtained CE certification for extracorporeal tubing sets for blood purification and the FutureF20 Hemoadsorption Equipment; <p>2. Expanded product offerings to customers</p> <ul style="list-style-type: none"> ○ Secured variation approvals for three models (A, B and C) of the DX-10 Blood Purification Machine; ○ Obtained variation approvals for additional specifications of CRRT Tubing Sets; <p>3. Enhanced clinical usability and operational efficiency</p> <ul style="list-style-type: none"> ○ Optimized pre-flushing requirements for CA products, reducing saline volume from 3000 mL to 2000 mL, and obtained the variation approval.
Reinforce R&D platform development to improve both the quality and efficiency of research and development	Completed upgrades to the R&D management system, including enhanced requirements management functionality, streamlined process workflows, improved user operability, and upgraded functional management modules.
Strengthen R&D talent development and collaboration with internal and external research forces to boost overall R&D capacity	Conducted 5 R&D capability-building training sessions in 2025, reaching 357 participants, with an overall satisfaction score of 9.54 (out of 10), effectively enhancing the knowledge base and capabilities of R&D personnel.

2025 Indicator



Investment in R&D

19,844.53 RMB 10,000

Percentage of R&D Investment in Main Business Revenue

9.89%

Number of Patents Held

317 Item

Number of Invention Patents Held

133 Item

Number of Utility Model Patents Held

17 Item

Number of New Patents Granted in the Year

45 Item

Total Number of Trademarks

246 Item

Innovation-Driven Measures

Innovation Incentive Mechanism

Jafron has established a market-oriented, result-driven and multi-dimensional R&D incentive mechanism to systematically unlock innovation potential, supported by internal audit oversight to ensure compliant and effective implementation. Anchored by the *Regulations on Incentives for R&D Projects*, the Company standardizes the definition of projects and special initiatives, and clearly stipulates incentive allocation and bonus distribution ratios at the project initiation stage. For designated key projects, a dual-leadership model (principal and deputy project leaders) is adopted, with project leaders for performance-oriented initiatives required to oversee product quality and value realization throughout the full lifecycle. A structured project outcome evaluation mechanism has also been introduced, with assessment results serving as the basis for project acceptance and incentive disbursement. In parallel, we standardize team composition, evaluation criteria and bonus allocation methodologies. Complementary policies, including the *Regulations on Incentives for R&D Ideas*, extend coverage to patent generation and early-stage ideation. Supported by the independent assurance function of internal audit, these mechanisms ensure fairness and compliance while effectively enhancing the engagement and initiative of R&D personnel, and supporting technological innovation and the achievement of strategic objectives. In 2025, we implemented dozens of innovation incentives across project outcomes, patent outputs and employee-led initiatives, further reinforcing the effectiveness of our incentive mechanisms.

Industry-University-Research Cooperation

Jafron adheres to an open and collaborative innovation model, placing strong emphasis on partnerships with universities and research institutions. We are committed to translating cutting-edge scientific achievements into practical applications and advancing technological progress within the industry. By developing governance frameworks such as the *Regulations on Scientific Research External Collaboration* and the *Regulations on the Management of Postdoctoral Research Workstation*, we effectively integrate external technical resources and establish efficient collaboration and communication mechanisms. We've established in-depth partnerships with institutions such as the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Sun Yat-sen University Postdoctoral Research Workstation, Shenzhen National Innovation Center for Advanced Medical Devices, and Hexaell Biotech. Through these collaborations, we undertake joint research programs to address critical technical challenges and advance key innovation projects, thereby further strengthening the Company's core competitiveness.

In addition, we have co-founded a Multi-Organ Support Therapy (MOST) Expert Committee with several world-renowned experts in clinical research and critical care medicine. The committee aims to provide robust evidence and new solutions for the global clinical application of MOST.

Joint Laboratory for High-Quality Dialysis Products

Case


In February 2025, Jafron, in collaboration with Huanggang Normal University, established a Joint Laboratory for High-Quality Dialysis Products. The laboratory focuses on key research areas in blood purification equipment and related advanced technologies. By integrating academic resources and building an open innovation platform, it provides strong support for the Company's strategic initiatives and enhances its long-term competitiveness.

Two Hemoadsorption Technologies Showcased at ASN Kidney Week

Case

From November 5 to 9, 2025, ASN Kidney Week was held in Houston, United States. During the conference, two clinical research abstracts—covering the pHA130 novel electrostatic hemoadsorption system and the established HA330 Disposable Hemoperfusion Cartridge—were accepted and published. This recognition demonstrates that the Company's innovative technologies have not only achieved broad clinical adoption domestically but have also gained recognition within the global academic community, contributing a "Jafron solution" to the advancement of blood purification technologies worldwide.

SEM analysis of platelet adhesion and activation on adsorbent surfaces



POSTER/FRIDAY: DIALYSIS: HEMODIAFILTRATION, ULTRAFILTRATION, PROFILING, AND INTERDIALYTIC SYMPTOMS

pHA130 Electrostatic Hemoadsorption System: A Material-to-Clinic Approach for Precision Removal of Protein-Bound Uremic Toxins

FR-PO0502

Cheng, Wang¹; Jianting, Ke¹; Yuting, Wei¹; Ying, Guo²; Qizhan, Lin¹; Li, Zhongxin¹; Nan, Gong¹; Jihao, Hu¹; Hu, Liu¹; Ke, Shao¹; Yanhui, Gong¹; Wenkai, Xiao¹

Author information

Journal of the American Society of Nephrology 36(10):101681/ASN.2025vcdqt6a, October 2025. | DOI: 10.1681/ASN.2025vcdqt6a

Participation in the Formulation of Standards

Jafron actively engages with domestic and international standardization bodies and participates in the formulation and drafting of national, industry and local standards, as well as clinical guidelines. By translating internal innovation practices into industry-wide norms, we not only strengthen our competitive positioning, but also contribute to the standardization and regulatory advancement of the medical device industry.

Selected Standards or Guidelines Contributed To

Name of Standard	Standard Type
Hemodialysis and Related Therapies – Hemodialyzers, Hemodialysis Filters, Hemodiafilters and Hemoconcentrators	Industry Standard
Disposable Plasma Bilirubin Adsorption Column	Industry Standard
Disposable Hollow Fiber Plasma Separator and Plasma Component Separator	Industry Standard
Cardiopulmonary Bypass Systems – Heparin Coating and Determination Method for Dimethylacetamide (DMAC) Residues in Extracorporeal Circulation Medical Devices	Industry Standard
Clinical Practice Guidelines for Disposable Hemoperfusion Cartridges	Group Standards
Clinical Practice Guidelines for Extracorporeal Tubing Sets for Blood Purification	Group Standards
YY/T 0464-2019 Disposable Hemoperfusion Cartridges	Industry Standard
Guidelines for On-Site Inspection of Medical Devices – Hemodialyzers	Industry Standard

Participation in Industry Exchanges

In 2025, Jafron continued to strengthen engagement and collaboration with the medical device communities. We actively participated in domestic and international academic conferences and trade exhibitions in fields such as nephrology, hepatology, critical care and sub-health. By participating in these events, we engaged in in-depth exchanges on the latest industry developments, cutting-edge technologies and research outcomes, while sharing knowledge and expertise to jointly advance technological progress and research in the medical device field—ultimately benefiting more patients.



CSN Critical Care & Blood Purification Congress



Congress of the Chinese Society of Nephrology 2025, CCSN 2025



7-site Academic Roadshow across 26 Provinces on Extracorporeal Therapies



28th Annual Congress of the Chinese Society of Emergency Medicine, Chinese Medical Association



13th CN-Healthcare Conference of Hospital Management



2025 Annual Congress of the Nephrology Committee of the Chinese Association of Integrative Medicine



The 13th National Conference of the CNSLD



43rd Vicenza Course on AKI-CRRT-EBPT

Protection of Intellectual Property Rights

Jafron places great importance on intellectual property (IP) protection and management. In strict accordance with the *Patent Law of the People's Republic of China* and other relevant laws and regulations, and based on the Company's actualities, we've formulated the *Patent Management Regulations* to regulate patent application, incentives and maintenance activities. We've established a patent classification and evaluation system and built an information platform to support lifecycle IP management. During the reporting period, the Company has been certified under the GB/T 29490-2013 Intellectual Property Management System and has been recognized as a "National Intellectual Property Demonstration Enterprise".



IPR Management System Certification



National Intellectual Property Demonstration Enterprise

Throughout the full product development lifecycle, Jafron initiates patent and trademark planning at the project approval stage and conducts internal patent applications, evaluations and infringement risk assessments for core technologies. Leveraging the self-developed "Jafron Blood Purification Technology Patent Database", we conduct real-time monitoring of industry patent dynamics. Through a structured process encompassing pre-project patent search and analysis, in-process patent portfolio planning and pre-launch infringement screening, we ensure that each intellectual property asset is secured with clear commercial intent and a solid technological foundation. A dedicated legal team is in place to manage potential infringement risks, establishing a comprehensive IP protection framework spanning R&D, manufacturing and commercialization activities. During the reporting period, the Company recorded no IP infringement incidents, effectively safeguarding the autonomy, security and market competitiveness of its core technologies and products.

Science and Technology Ethics


Jafron strictly adheres to applicable laws, regulations and medical ethical principles in key areas of technology ethics, including data privacy protection and the ethical review and responsible application of scientific achievements, such as the *World Medical Association Declaration of Helsinki*, ensuring that technological innovation is pursued in parallel with the fulfillment of social responsibility. During the Reporting Period, the Company did not experience any major violations related to science and technology ethics.

Animal Experiments

The Company has established an Institutional Animal Care and Use Committee (IACUC). Its laboratory animal facilities within the Science Building are licensed for animal use. All animal experiments are conducted in strict compliance with the following regulations and guidelines: *GB 14922-2022 Laboratory Animal—Microbiological and Parasitological Standards and Monitoring*, *the Regulations on the Administration of Laboratory Animals*, *the Guiding Opinions on the Humane Treatment of Laboratory Animals* and *GB/T 35892-2018 Laboratory Animal—Guideline for Ethical Review of Animal Welfare*. The Company has developed a comprehensive set of laboratory management systems and standard operating procedures to ensure that all production activities respect animal life and welfare and uphold public ethical standards.

Medical Device Clinical Trials

In the field of clinical trials for medical devices, Jafron strictly adheres to applicable laws, regulations and ethical standards, including the *Regulations on the Supervision and Administration of Medical Devices* and the *Regulations on the Administration of Registration and Filing of Medical Devices*, ensuring that all clinical trials align with the principles of protecting subject rights, data authenticity and risk controllability. Through ethical reviews, subject rights protection and data security management, the Company complies with both domestic and international laws and ethical standards, ensuring its scientific research activities are legal, safe, socially valuable and respectful of subject rights.



Ethics Awareness Development

To enhance employees' knowledge and skills in animal ethics, the Company conducts training on science and technology ethics through a combination of internal and external programs, based on its annual training plan. The training covers topics such as ethical principles for professionals, laboratory animal specifications, biosafety related to laboratory animals, and regulatory requirements for clinical trials of medical devices. We are committed to continuously improving our tiered training system, facilitating the transformation of ethical awareness into practical execution, and building a dual-driven mechanism of "Technological Innovation + Ethical Safeguards" to ensure a sustainable balance between research value and the rights of trial subjects.

Jafron Organizes Specialized Training on Supervision over Clinical Trials of Medical Devices

Case



Medical Accessibility

Jafron remains focused on its core business and remains committed to science and technological innovation, continuously deepening its presence in nephrology, hepatology, critical care and sub-health-related fields. We actively expand the boundaries of clinical applications and are dedicated to providing high-quality products and solutions for patients with critical and complex conditions, including uremia, severe liver disease and systemic lupus erythematosus.

In the nephrology field, the Company continues to strengthen engagement with existing hospital networks by implementing screening programs and patient education initiatives for dialysis-related complications, enabling earlier identification of patients requiring treatment and improving the penetration rate of hemoperfusion therapy among uremia patients. We also continue to expand our product portfolio, providing preventive and therapeutic solutions across all stages of dialysis and for different types of complications, thereby more comprehensively addressing the clinical needs of maintenance hemodialysis patients.

In the hepatology field, the Company has established multiple regional model artificial liver centers across China. Leveraging these centers as demonstration hubs, we continue to promote the clinical adoption and standardization of the double plasma molecular absorb system (DPMAS) technology. During the reporting period, we conducted multiple training programs on blood purification diagnosis and treatment for liver failure, hands-on clinical observation sessions and patient education activities, thereby improving the standardization and quality of artificial liver blood purification practices.

In the field of emergency and critical care, the Company focused on technology dissemination and ecosystem development in emergency medicine in 2025. Through a dual-engine approach comprising the "Emergency Blood Purification China Tour" and standardized training programs for acute poisoning diagnosis and treatment, we promoted the wider adoption of hemoadsorption technologies in emergency settings. We've preliminarily established a nationwide network of emergency medicine experts centered around the Chinese Medical Association and the Chinese Medical Doctor Association. Technical training and educational programs have been conducted across multiple provinces and municipalities, enhancing clinical awareness and understanding of hemoadsorption technologies in emergency care.

In terms of product and technology accessibility, the Company continues to expand its domestic and international presence. A range of clinical technologies and products have been deployed in more than 8,000 hospitals across over 90 countries and regions, achieving the goal of "Created in China, Made for World" and contributing to improved global health outcomes. In addition, the Company remains committed to its founding principle of "making high-quality medical technologies accessible to more patients". We continue to strengthen healthcare capacity in primary care institutions and underserved regions. Through public welfare donations, technology transfer and inclusive healthcare initiatives, we are steadily improving healthcare accessibility and helping to address key challenges such as limited access to care, treatment affordability and geographic disparities in healthcare provision.

At the same time, we promote health education through channels such as the Jafron WeChat official account and the i-DO patient management service platform, offering product knowledge sessions, expert lectures and real-world patient stories.

Safety and Quality of Products and Services

Jafron strictly complies with applicable laws and regulations, including the Product Quality Law of the People's Republic of China and the Good Supply Practice for Medical Devices. Guided by its quality policy—"Building Excellence through Expertise, Winning through Quality and Serving with Integrity."—the Company has established a robust, well-structured quality management system to ensure consistent, lean and effective control over product quality and safety. During the reporting period, the Company reported zero major quality incidents and received no large-scale quality-related complaints.

Governance

Jafron has established a comprehensive set of quality management policies, including the *Quality Manual and the Product Assurance Control Procedures*, to provide a strong institutional foundation for quality management. A full lifecycle quality management framework has been implemented, covering product design, manufacturing, distribution and post-market services. The General Manager serves as the principal accountable person for medical device quality and assumes overall responsibility for product quality and safety. The General Manager leads the establishment of a long-term accountability mechanism for quality and safety, organizes periodic management reviews, reviews quarterly reports from the Management Representative, and coordinates key initiatives related to quality risk prevention and control. In parallel, all functional departments operate in accordance with clearly defined responsibilities and authorities set out in the quality system documentation, ensuring rigorous implementation of quality control requirements across the entire product lifecycle.

As of the end of the reporting period, the Company and its major subsidiaries have successfully obtained ISO 9001 quality management system certification and ISO 13485 medical device quality management system certification.



Some Quality Management System Certification Certificates

Strategy

To ensure sustained product quality, Jafron systematically identifies and assesses potential risks and opportunities related to product quality. For identified risks, targeted mitigation measures are implemented based on risk characteristics, quality requirements and applicable regulatory standards, thereby reducing quality-related exposure. At the same time, we actively capture opportunities to enhance product quality and strengthen market competitiveness.


Risk Type	Description of Risk	Impact Duration	Potential Financial Impact	Countermeasures
Risks from Changes in Laws and Regulations	Hemoperfusion products are subject to rigorous regulatory oversight related to manufacturing, marketing authorization and corporate qualifications. Enterprises must swiftly adapt to evolving laws to ensure ongoing compliance.	Medium term	Increased compliance and operating costs	<ul style="list-style-type: none"> Conduct regular reviews of policies and regulations; ensure timely product certifications to ensure product compliance with established standards
Product Safety Risk	As our core product – the disposable hemoperfusion cartridge – comes into direct contact with human blood, the product safety is critical to patient lives and health. Any compromise in product safety may result in serious medical incidents, potentially harming brand reputation. This could lead to production halts, a loss of market share and a reduction in sales.	Medium to long term	Increase in operating costs and decrease in operating revenue.	<ul style="list-style-type: none"> Strengthen quality control through comprehensive quality management Perform routine inspections and monitoring to identify potential quality issues Provide quality training to enhance employee expertise in product knowledge and equipment operation
Product quality or customer complaints	Post-sale quality issues or customer complaints, especially mass returns, can significantly undermine brand reputation and customer loyalty.	Short term	Increased operating costs and reputational loss	<ul style="list-style-type: none"> Establish a responsive and robust after-sales service system to capture feedback and drive continuous improvement in product design and service quality Maintain a proactive product recall mechanism to ensure swift response to and resolution of any quality incidents

Opportunity Type	Description of Opportunity	Impact Duration	Potential Financial	Countermeasures
Product Market Opportunities	Growing demand for higher safety and quality standards in medical devices offers the Company an opportunity to upgrade product offerings, elevate brand value and capture greater market share.	Medium to long term	Increased pricing, sales and revenue	<ul style="list-style-type: none"> Deepen R&D of core products by upgrading HA and KHA series disposable hemoperfusion cartridges, accelerating the commercialization of new products such as CRRT filters, and reinforcing core technological barriers in adsorption materials. Leverage the CNAS-accredited national laboratory to enhance advanced benchmarking testing capabilities and ensure stringent quality control across the entire production process.
Product Upgrade Opportunities	The continued evolution of intelligent manufacturing and digital transformation enables the Company to enhance service quality and operational efficiency by leveraging automation and other technologies.	Medium to long term	Reduction in Production Costs	<ul style="list-style-type: none"> Introduce automated manufacturing equipment and AI-enabled quality control technologies to optimize key processes such as resin screening and filling. Establish a digital service platform covering equipment operation and maintenance, as well as patient follow-up and related service scenarios, to enhance customer engagement and retention.

Note: Impact Duration: refers to the different periods when different climate-related risks and opportunities will affect the Company. The Company categorizes the impact duration into short term (0-1 year), medium term (1-5 years), and long term (over 5 years).

Impact, Risk, and Opportunity Management

Jafron places high priority on the identification and management of risks and opportunities associated with product and service safety and quality. We've established an institutional framework centered on the *Risk Management Control Procedures*, which clearly define risk management processes, roles and responsibilities. Through routine, end-to-end risk management practices, we ensure comprehensive coverage across the full lifecycle of blood purification devices—from design and development, manufacturing and clinical application to end-of-life disposal—thereby ensuring that risks at each stage are systematically identified and controlled within acceptable limits.



Metrics and Targets

In alignment with applicable regulatory requirements, customer demands and the Company's strategic objectives, we've established quality and safety targets spanning the entire product lifecycle, continuously driving improvements in quality management performance.

Quality Target	Achievements in 2025
Major (or above) quality incidents = 0; serious quality incidents ≤ 1	✓ Achieved
Number of recalls due to quality issues: 0	✓ Achieved

2025 Indicator



First Pass Yield
100%


Number of Internal Quality Audits Conducted
2 Times

Incidence Rate of Major Quality Incidents
0

Product Quality Control

Lifecycle Quality Management

Guided by key domestic and international regulatory standards, Jafron has developed a comprehensive set of procedural documents and specifications, including the *Production Process Control Procedures* and the *Product Protection Control Procedures*. These form an integrated lifecycle management system covering product planning, design and development, procurement, manufacturing, delivery and after-sales services. Risk management, compliance control and process validation are embedded throughout all stages of the product lifecycle. In addition, we employ a combination of incoming inspection, in-process sampling and independent third-party testing to proactively identify and mitigate quality risks. This approach ensures that all products—including disposal hemoperfusion cartridges and blood purification equipments—are effectively controlled at every stage, from initial concept through to market withdrawal, enabling the consistent delivery of safe, effective and compliant medical devices that meet global market and customer expectations.




Control of Hazardous Substances

Beijing Jafron has established the *RoHS Control Procedures* tailored to the specific characteristics of its medical device products and implemented a comprehensive, multi-dimensional hazardous substance management system covering the entire product lifecycle. This system focuses on the effective control of hazardous substances in raw materials, manufacturing processes and finished products, ensuring that all products meet safety and compliance standards as well as applicable RoHS requirements and environmental and safety standards.


Monitoring Scope	Processes Covered	Key Monitoring Items
Raw Materials/ Components	Procurement Qualification, Incoming Inspection	1. Metallic materials: heavy metals such as lead, cadmium and mercury; 2. Polymer materials: plasticizers and residual monomers; 3. Electronic components: restricted hazardous substances; 4. Packaging materials: migratory hazardous substances.
Production Process	In-process Inspection and Environmental Monitoring	1. Process water: microorganisms, endotoxins and chemical contaminants; 2. Production environment: particulates and microbial levels in controlled clean areas; 3. Sterilization processes: residual sterilants (e.g., ethylene oxide).
Finished Products	Final Release Testing and Type Testing	1. Residual levels of hazardous substances; 2. Biocompatibility-related parameters; 3. Sterility assurance and particulate contamination for sterile medical devices.

Nonconforming Product Control and Product Recall

Jafron has established the *Non-conforming Product Control Procedures*, defining a closed-loop management mechanism and handling process encompassing "identification-segregation-evaluation-disposal-improvement". This framework is designed to prevent unintended use or delivery of non-conforming products and to safeguard patient safety.



To ensure timely and effective response to potential quality incidents, Jafron has implemented policies including the *Field Safety Notification*, *Product Recall and Information Disclosure Control Procedures* and the *Product Recall Control Procedures*. We've established a comprehensive recall management system under which cross-functional teams from Quality Management, Customer Service and Sales are responsible for issuing domestic field safety notices and executing recalls of medical devices. These teams conduct timely root cause analyses, provide supplemental information and guidance and implement corrective actions to ensure that any potentially defective products are promptly removed from the market – minimizing adverse impacts associated with quality issues and safeguarding the health and safety of patients and healthcare professionals.



Post-Marketing Surveillance and Control

Jafron has established a robust post-market surveillance (PMS) system covering both domestic and international markets, in accordance with the *CE Product Post-market Surveillance Control Procedures*. This system supports full lifecycle safety management of medical devices, with particular focus on core products such as disposable hemoperfusion cartridges and blood purification equipments.

Prior to product launch, we develop a dedicated *Post-market Surveillance Plan* for each product line, clearly defining the scope of data collection, including clinical usage data, adverse event reports, customer complaints, market sampling results, and supplier quality feedback. These data streams are integrated with the Unique Device Identification (UDI) system to enable end-to-end traceability, ensuring precise linkage to specific product batches and use scenarios.

Following data collection, the Quality Management Department, in collaboration with the Customer Service Department and Quality Inspection Department, performs integrated data analysis to identify quality trends and emerging risks. *Periodic Safety Update Reports (PSURs)* are prepared in accordance with regulatory requirements to support ongoing product safety evaluation. For CE-marked products, Post-Market Clinical Follow-up (PMCF) Plans are established and executed, with corresponding reports generated to meet the requirements of the EU Medical Device Regulation (MDR).

Where potential risks are identified, corrective and preventive actions (CAPA) are promptly initiated, including process optimization, issuance of advisory notices, and, where necessary, product recalls. The Internal Audit Department conducts quarterly reviews of PMS implementation, while supporting inspections by regulatory authorities and EU-notified bodies. This closed-loop governance mechanism ensures patient safety.

Evidence-Based Product Validation

Jafron places strong emphasis on clinical validation and the generation of evidence-based medical data, guided by the principle of "substantiating efficacy through evidence and advancing development through scientific research". We've conducted multiple clinical studies in key therapeutic areas, including hepatology and nephrology. Through systematic academic engagement and the continuous accumulation of clinical evidence, we've progressively established a robust evidence base supporting the safety and effectiveness of our products. Relevant research findings have been published in leading domestic and international academic journals and have contributed to the development of clinical practice guidelines.

Quality Culture Development

To effectively implement its quality policy, Jafron actively promotes organization-wide participation in quality management. A structured and comprehensive quality training system has been established to enhance employees' quality awareness and technical competencies. An annual quality training plan is developed and rigorously executed for all employees, covering key areas such as product knowledge, adverse event monitoring, manufacturing quality control, facility and equipment management, and applicable medical device regulations. In 2025, the Company continued to roll out quality-focused training and communication initiatives, ensuring that employees remain fully aligned with the latest quality management standards and product requirements.

Key Performance

Participants in Quality Training

4,197 Person-times

Total Duration of Quality Training

8,188 Hours


Sessions of Quality Training

18 Sessions

Specialized Training on Regulatory and Quality Management System Requirements

Case

To effectively advance the Quality Year initiatives and further standardize end-to-end quality control throughout production, Jafron's Production Department organized specialized training sessions on regulatory and quality management system requirements. The training focused on industry laws and regulations, quality management system standard clauses, role-specific compliance points, and practical management practices. By analyzing real-world work cases, the sessions provided in-depth explanations of core requirements, helping the staff clarify management boundaries and master compliance workflows. Through systematic learning, the training strengthened employees' legal awareness and system consciousness, ensuring the practical implementation of all management system requirements.



Customer Service

Customer Service Management

Jafron adheres to its service philosophy of "Integrity in Service: Customer satisfaction is the ultimate objective of all our efforts". Guided by customer needs and underpinned by both product quality and service excellence, we continuously optimize service processes and enhance customer engagement, progressively building a customer-centric service ecosystem. By formulating governance frameworks such as the Customer Service Management System, the *Customer Feedback Response Control Procedures* and the *After-sales Service Control Procedures*, we've established clear standards for after-sales service delivery and customer feedback management. The Customer Service Department serves as a dedicated function responsible for customer communication, feedback management, satisfaction surveys and relationship maintenance, providing a solid foundation for consistent, high-quality service delivery.

Established in 2002, the Customer Service Center is staffed entirely by female professionals with medical expertise. Since its inception, the center has provided **24/7** support services, handling over **300,000** customer interactions annually and serving more than **6,000** hospitals nationwide. It delivers comprehensive technical support across the entire customer support process—from pre-sales consultation to post-sales service—while regularly disseminating academic updates and industry insights. In addition, the Company conducts systematic product and service evaluations to capture customer feedback and inform continuous product iteration and service enhancement. These efforts support the ongoing professionalization, standardization and human-centered evolution of the Company's customer service model, reinforcing its commitment to delivering high-quality, patient-centric service. During the reporting period, Jafron's Customer Service Center was honored with the title of "National March 8th Red-Banner Collective".



Customer Satisfaction

Jafron regards customer satisfaction as a core indicator of service quality. To support this, we've established governance frameworks including the *Customer Feedback Monitoring and Management Policy* and the *Customer Satisfaction Monitoring Management System*. Leveraging multi-channel data collection—such as comprehensive surveys, sample-based assessments, and digital platforms including the official WeChat account—the Customer Service Department conducts ongoing monitoring and quantitative analysis of hospital customers' product usage experience, enabling the tracking of satisfaction trends over time. Guided by customer expectations, we continue to strengthen trust-based relationships with our customers, enhancing overall satisfaction levels while reinforcing brand credibility and market trust.

Key Performance

During the reporting period, a total of **480** customers participated in the customer satisfaction survey, with **574** valid questionnaires distributed; and the average customer satisfaction rating stood at **97.14%**.

Note: The overall customer satisfaction is calculated by averaging the following satisfaction measures—Adsorbent category: 98.8%, Equipment category: 97.1%, Tubing category: 97.2%, Plasma Separator/Hemodialyzer category: 92.6%, Bandage category: 100%.

Handling of Customer Complaints

Adhering to a customer-centric approach, Jafron has established a robust after-sales service system supported by dedicated policies, including the *Complaint Control Procedures*, the *Customer Complaint Reception and Handling Management Policy*, and the *Hemoperfusion Product Complaint Control Procedures*. Led by the Quality Management Department, a dedicated task force conducts comprehensive, end-to-end investigations of each complaint. These investigations cover multiple dimensions, including product quality status, the correlation between reported issues and product performance, compliance in product use, and compliance throughout the distribution process. Based on the findings, root causes are identified and the relationship between the issue and product quality or service performance is systematically assessed. This structured mechanism ensures that customer complaints are received, investigated, evaluated and resolved in a timely, objective, and effective manner. At the same time, customer feedback and suggestions are promptly addressed and, where appropriate, incorporated into continuous process improvements, further strengthening the Company's complaint management framework.

Responsible Marketing

Jafron strictly complies with applicable laws and regulations, including the *Advertising Law of the People's Republic of China* and the *Law of the People's Republic of China on the Protection of Consumer Rights and Interests*. We've established internal governance frameworks such as *Jafron's Manual for Marketing Compliance Management System* and the *Marketing Promotion Compliance Guidelines* to reinforce compliance across all marketing activities. In academic promotion, technical marketing and brand communication, we strictly prohibit exaggerated or misleading claims, ensuring that all marketing practices are conducted in a lawful, ethical and transparent manner so as to safeguard consumer rights and uphold fair market practices.

During the reporting period, the Company offered **18** training sessions on responsible marketing, and no violations related to marketing activities occurred.

Training on Responsible Marketing

Case



Information Security and Data Protection

Jafron strictly adheres to applicable national data security regulations and is committed to establishing a long-term, robust framework for data security and privacy protection. By integrating compliance governance, technical safeguards and risk management controls, we provide strong assurance for the protection of customer privacy and support digital transformation. During the Reporting Period, no violations related to information security or privacy protection occurred in the Company.

Information Security Management

Jafron complies with applicable laws and regulations, including the *Cybersecurity Law of the People's Republic of China* and the *Data Security Law of the People's Republic of China*, and aligns its information security practices with the *ISO/IEC 27001 Information Security Management System*. We've formulated the *General Information Security Policy*, systematically governing key areas such as routine system operations, security control measures, data storage and data transmission protocols, to ensure information security across business operations. These measures are designed to prevent unauthorized disclosure of know-how and business secrets and to safeguard the Company's core competitiveness.

At the organizational level, we've established a structured information security governance framework. An Information Security Steering Committee, composed of senior management, serves as the highest decision-making body for information security matters, ensuring strong executive oversight and support. The Information Security Department, serving as the oversight body of information security, is responsible for establishing and maintaining the Company's Information Security Management System (ISMS). In addition, each department assigns full-time or part-time information security personnel, while key business units establish dedicated roles responsible for implementing security policies, standards, and procedures, as well as conducting compliance inspections and security incident investigations. The Information Security Department maintains regular coordination with business units to ensure that all security controls are appropriately aligned with business risk profiles.

The i-Do Chronic Disease Management System and Yuebao Insurance System have obtained Tier-3 data security protection certifications, while the Yuebao official website system has obtained Tier-2 data security protection certification.



Information Security Management

To continuously strengthen its information security capabilities and ensure the confidentiality and integrity of business data, Jafron has implemented a comprehensive set of control measures to build a secure and reliable network environment.

Data Classification and Encryption Management

The Company implements tiered classification for data and information assets, clearly defining protection scopes and control requirements for critical, important and general data. A Data Loss Prevention (DLP) system has been deployed to enable document classification, hierarchical protection and real-time encryption. Strict access controls are enforced for external transmission and decryption permissions, with asset labeling and transmission auditing mechanisms in place to ensure full traceability and auditability of data operations. All sensitive documents must undergo approval and declassification before being transmitted externally. External transmission permissions are subject to regular review, and non-compliant access rights are dynamically revoked. These measures are designed to prevent unauthorized access, leakage, alteration, destruction or misuse of data belonging to suppliers, customers and employees.

Risk Assessment

The Company has established a structured information security risk identification mechanism and strictly implements a standardized risk management process. Potential risks are identified across key domains, including device security, data security, physical security and network security. Identified risks are subject to a comprehensive assessment and classified accordingly. Targeted mitigation strategies are then developed, with clearly defined corrective actions, accountable owners and rectification deadlines.

Security Audits

The Company conducts periodic information security audits to evaluate the effectiveness and compliance of existing control measures, and to monitor the implementation status of corrective actions for identified risks.

Attack and Defense Drills

The Company regularly organizes relevant personnel to address cybersecurity vulnerabilities and high-risk issues. We simulate data recovery following system outages caused by external attacks and perform disaster recovery drills to enhance our emergency response capabilities for unforeseen incidents, thus ensuring timely and effective protection of information assets. During the Reporting Period, the Company conducted 2 information safety emergency drills.

Selected Disaster Recovery Drill Results			
System	Impact Level	Drill Scenario	Recovery Time
AD Domain	Level 1	AD domain outage; system unable to start	25 minutes
Netdisk	Level 1	Network drive outage; system unable to start	50 minutes
OA System (Cluster)	Level 1	Disk failure; data restoration performed to validate backup availability	120 minutes
SAP (HANA Database)	Level 1	SAP system outage; system unable to start	120 minutes
EHR	Level 1	Disk failure; data restoration performed to validate backup availability	240 minutes
Email	Level 3	Email system outage; system unable to start	120 minutes
Corporate Website	Level 1	Migration from backup database to snapshot-based backup architecture	30 minutes
New GIPDIS	Level 2	Disk failure; data restoration performed to validate backup availability	30 minutes

Training on Information Security

To ensure employees are fully aware of information security risks and requirements relevant to their roles, Jafron conducts regular training and awareness programs for full-time or part-time information security personnel across departments. Employees are required to maintain strong information security awareness in their daily operations, enhancing their ability to identify and mitigate data security risks. During the reporting period, the Company delivered targeted capability-building training for part-time information security officers across its branches. The training covered topics including AI applications and associated security risks, secure file backup practices and email security, supported by case studies and hands-on exercises. Training effectiveness was assessed to further strengthen the professional competence and execution capability of information security personnel, thereby reinforcing the Company's overall cybersecurity defense framework.

Key Performance

Number of Training Sessions on Data Security/Customer Privacy Protection

2 Times

Coverage Rate of Training on Data Security/Customer Privacy Protection

100%

Per Capita Training Hours for Training on Data Security/Customer Privacy Protection

2 Hours

Customer Privacy Protection

Jafron strictly complies with applicable laws and regulations and maintains robust confidentiality controls over customer information and data security. Prior to the use of products and services such as "i-Do" and "Yuebao", users are fully informed through the *Privacy Policy* regarding the categories of personal information collected and the purposes of use. Upon obtaining users' authorization and consent, the Company processes personal information in strict accordance with the agreed terms and implements comprehensive data confidentiality and security safeguards. The Company respects and protects the privacy rights of all users and customers, ensuring the security and confidentiality of customer data.

隐私政策

1. 适用范围

2. 我们收集哪些个人信息

3. 我们如何使用您的个人信息

4. 我们如何保护您的个人信息

5. 我们如何共享您的个人信息

6. 您的权利

7. 联系我们

隐私政策

1. 适用范围

2. 我们收集哪些个人信息

3. 我们如何使用您的个人信息

4. 我们如何保护您的个人信息

5. 我们如何共享您的个人信息

6. 您的权利

7. 联系我们

Privacy Policy

Responsible Supply Chain

Jafron places strong emphasis on coordinated development across the industrial value chain and continues to deepen collaboration with partners at all stages of the supply chain. By continuously enhancing its supply chain governance system, the Company systematically embeds ESG requirements into the full lifecycle of supplier management, ensuring secure, stable and efficient supply chain operations while promoting shared value creation across the industry.

Governance

Jafron strictly complies with applicable laws and regulations, including the *Bidding Law of the People's Republic of China* and the *Regulation on the Implementation of the Bidding Law of the People's Republic of China*. It has established the *Group-level Supplier Management System* and the *Procurement Control Procedures*, which clearly define standardized operating requirements for each procurement stage and lifecycle management principles for suppliers. A centralized Procurement Supply Center has been established to oversee unified management, under which multiple procurement units operate independently to conduct procurement of goods and services, thereby broadening procurement coverage.

Management Structure and Responsibilities

Procurement and Supply Center

- Responsible for the management of core suppliers, key suppliers and specially designated procurement suppliers.
- Develop group-wide supplier management models and rules, and maintain the "Group-level Supplier Database".
- Conduct audits and oversight of supplier management practices across all procurement units.

Procurement Units

- Responsible for the management of key suppliers, specially designated suppliers and general suppliers.
- Develop and implement supplier management policies in accordance with the group-wide supplier management models and rules.

The Company's Procurement Supply Center has established a structured learning and development platform aligned with procurement professionals' career progression, and has developed a multi-dimensional training system incorporating mentorship programs and best-practice sharing among high-performing employees to enhance procurement expertise and management capabilities. A supporting training evaluation and incentive mechanism has been implemented to strengthen employee engagement and foster a professional, efficient and learning-oriented procurement team. During the reporting period, the Procurement Supply Center conducted **7** training sessions totaling **9.41** hours.

Procurement Training

Second Quarter



Third Quarter



Fourth Quarter



Strategy

Jafron proactively identifies and addresses a range of challenges affecting the stable operation of its supply chain, while continuously exploring emerging opportunities within its sustainable development agenda. While ensuring business continuity and regulatory compliance, the Company is committed to advancing the sustainable growth of its supply chain and enhancing overall value creation.


Risk Type	Description of Risk	Impact Duration	Potential Financial Impact	Countermeasures
Supply Disruption Risk	Supplier capacity limitations or delivery delays may result in production setbacks and inventory shortages, affecting production schedules.	Short term	Reduced revenue and profit; increased procurement costs	<ul style="list-style-type: none"> Build a strategic reserve of key raw material suppliers Deploy R&D staff to provide technical support and oversight; regularly review and monitor suppliers' quality standards to ensure product compliance Offer training to suppliers to help them enhance production processes and quality controls
	Insufficient quality control by suppliers may lead to product defects, impacting company reputation and customer satisfaction and even leading to potential recalls and legal consequences.	Medium term	Increase in production costs	
Price Fluctuation Risk	Raw material shortages, regional pricing differences and market fluctuations may drive up material costs.	Short and medium term	Increase in procurement costs	<ul style="list-style-type: none"> Adjust procurement strategies dynamically based on market trends Improve procurement timing strategies to optimize cost control

Opportunity Type	Description of Opportunity	Financial Impact	Impact Duration
Promote digital transformation	Leveraging information technology to enable supply chain visibility and real-time monitoring, thereby improving transparency and operational coordination efficiency.	Reducing Operational Costs	Medium to long term
Opportunities in Green Supply Chains	Developing a green supply chain through green procurement and green logistics practices, aligned with government carbon peaking and carbon neutrality goals, enhancing corporate social responsibility performance, and capturing policy-driven incentives and market opportunities.	Increased revenue and improved profitability	Medium to long term

Note: Impact Duration: refers to the different periods when different climate-related risks and opportunities will affect the Company. The Company categorizes the impact duration into short term (0-1 year), medium term (1-5 years), and long term (over 5 years).

Impact, Risk, and Opportunity Management


Jafron has established a robust supply chain risk management framework. We conduct periodic assessments to quantify supplier-related risks across key dimensions, including technology, quality and cost, while actively identifying and leveraging supply chain development opportunities to support long-term, sustainable growth.



Metrics and Targets


In light of business development needs, Jafron has established annual indicators and targets across procurement operations and supplier management, and continuously tracks progress toward target achievement. Through clear target-setting and management, we enhance coordination across the supply chain to radically improve overall operational efficiency and governance effectiveness.

Group	Goals by 2025	Progress in 2025
Procurement Business Management	First-pass acceptance rate of raw and auxiliary materials $\geq 97\%$	✔️ Achieved
	Completion of corrective actions for all audit non-conformities within the year	✔️ Achieved
Supplier Management	Increase the proportion of suppliers rated "Excellent" or above Develop new suppliers	✔️ Achieved



Supplier Lifecycle Management

Jafron has established standardized management systems and stringent review processes that clearly define supplier selection, onboarding, audit and performance evaluation procedures. We continuously strengthen supplier collaboration quality to ensure alignment with the Company's strategic development and operational requirements. Suppliers are required to consistently meet high standards in product quality, delivery timeliness and service performance, thereby supporting us in maintaining a competitive position in the market.



Supplier ESG Management

Jafron regards responsible supply chain management as a key component of its ESG strategy and is committed to building an integrity-based ecosystem in collaboration with its partners. Jafron has established the *Procurement Integrity Management Policy*, which clearly defines the procurement management scope, procedures and requirements. All procurement staff are required to perform their duties in strict compliance with applicable laws and regulations. Prior to starting work, procurement personnel must sign the *Procurement Personnel Integrity Commitment*. We've further strengthened procurement process oversight mechanisms and enhanced integrity training and communication for both procurement personnel and suppliers. We maintain a zero-tolerance policy toward any form of commercial bribery, improper benefits transfer or other corrupt practices, ensuring procurement activities are conducted in a fair and transparent and compliant manner, thereby safeguarding the Company's reputation.

During the reporting period, the signing rate of the Procurement Personnel Integrity Commitment reached **100%**, while the signing rate of Supplier Integrity Commitment increased by **17** percentage points year-on-year.

ESG-Focused Procurement Training

Case

To further implement its ESG strategy and advance green procurement practices, Jafron conducts periodic ESG-focused procurement training programs. External ESG experts are invited to deliver targeted training sessions to procurement personnel and relevant administrative staff, covering key topics such as green supply chain management, low-carbon product selection, supplier ESG evaluation, and compliance risk identification. Through case study, standards interpretation and hands-on exercises, the program strengthens employees' sustainability awareness and professional competencies, ensuring procurement activities systematically integrate environmental, social and governance considerations.



Digital Supply Chain

Jafron is committed to advancing the digital transformation of its supply chain and continuously enhancing its intelligence and level of modernization through technological innovation. By implementing an integrated management model linking the Jafron procurement platform (in-house procurement system), OA and SAP systems, the Company consolidates supplier management, procurement demand management, warehousing and settlement, and inventory management into a unified digital workflow. This enables intelligent coordination and data-driven operations across the supply chain, optimizing network structure, improving operational efficiency, reducing costs, and achieving transparency and full lifecycle traceability of product quality.



Consolidating the Foundation for Sustainable Development through Steadfast Governance

Jafron continues to optimize the operation of its Board of Directors and strengthen its internal control and risk management systems to ensure sound decision-making, effective oversight, and robust execution. The Company is committed to establishing a governance framework characterized by clearly defined rights and responsibilities, effective checks and balances, and coordinated and efficient operations. By strictly complying with applicable laws and regulations, upholding business ethics and practicing integrity-driven operations, the Company continuously enhances its governance capabilities, laying a solid foundation for long-term sustainable growth and value creation.

ESG Material Topics Covered in this Chapter

- Due Diligence
- Anti-Unfair Competition
- Anti-Commercial Bribery and Anti-Corruption

SDGs Responded in this Chapter



Governance

Governance Structure

In line with the *Company Law of the People's Republic of China* (the "Company Law"), the *Securities Law of the People's Republic of China* (the "Securities Law"), the *Code of Corporate Governance for Listed Companies* and other relevant laws and regulations, Jafron has formulated the *Articles of Association* and other internal control systems. We continuously strengthen our internal governance framework and refine internal control systems by clearly defining the respective responsibilities and authorities of decision-making, execution and oversight functions. We've established a governance structure comprising the Shareholders' Meeting, the Board of Directors, and the management team. This structure forms a well-defined, standardized and effectively balanced governance system, providing a solid foundation for compliant operations and sustainable development.

General Meeting of Shareholders

Jafron strictly complies with applicable laws and regulations, including the *Rules for the Shareholders' Meeting of Listed Companies*, and has formulated the *Rules of Procedure for Shareholders' Meetings* to standardize the convening and conduct of shareholders' meetings. Notices are issued to shareholders 15 or 20 days in advance of meetings. Lawyers are engaged to attend meetings on site and issue legal opinions. Resolutions are adopted through a combination of on-site and online voting, ensuring that shareholder decisions are made in a fair, open and transparent manner. All directors and senior management attend the shareholders' meetings and engage in in-depth communication with investors. For matters that may materially affect the interests of minority shareholders, separate voting for minority shareholders is implemented, fully safeguarding the legitimate rights and interests of all shareholders, particularly minority shareholders.

Key Performance

During the Reporting Period, the Company held **2** general meetings of shareholders, including **1** annual general meetings of shareholders and **1** extraordinary general meetings of shareholders, at which a total of **26** proposals were reviewed and approved.

Board of Directors

The Board of Directors of the Company, accountable to the General Meeting of Shareholders, reviews major matters in the business activities of the Company, and makes decisions or submits them to the General Meeting of Shareholders for approval. In strict compliance with the provisions and requirements of the *Company Law of the People's Republic of China*, the *Articles of Association* and the *Rules of Procedure of the Board of Directors*, the Company clarifies the scope of authority of the Board of Directors, improves and standardizes the operation of the Board of Directors in aspects such as the procedures of convening meetings and reviewing proposals voting, as well as voting modes and resolution content, thereby fully utilizing the decision-making role of the Board of Directors.

In 2025, the Company's Board of Directors strictly adhered to the resolutions and authorizations of the General Meeting of Shareholders, conscientiously implemented all resolutions passed by the General Meeting of Shareholders, and ensured the standardized operation of all Board activities. All directors exercised their duties in a standardized manner, attended the General Meeting of Shareholders, performance briefings, and investor communication meetings, and fully applied their professional knowledge and expertise to provide scientific support for the decision-making on major corporate matters.

Key Performance

During the reporting period, the Company convened a total of **14** meetings of the Board of Directors, at which **45** proposals were reviewed and approved.

Specialized Committees under the Board of Directors


The Board of Directors is supported by four specialized committees: the Strategy and ESG Committee, the Audit Committee, the Nomination Committee, and the Remuneration and Appraisal Committee. We've also formulated the Rules of Procedure for the Strategy and ESG Committee, the *Rules of Procedure for the Audit Committee*, the *Rules of Procedure for the Nomination Committee*, and the *Rules of Procedure for the Remuneration and Appraisal Committee* under the Board of Directors. Each governance body has clearly defined responsibilities, operates in a coordinated manner, and maintains effective checks and balances. Its deliberation and decision-making processes are rigorous, transparent, and democratic. These committees play a key role in supporting the Board in fulfilling its decision-making and supervisory responsibilities, thereby promoting standardized governance and sustainable corporate development.

Specialized Committees	Meetings of Specialized Committees (Times)	Independent Directors (Persons)	Proportion of Independent Directors (%)	Non-Independent Directors(Persons)	Whether independent directors serve as the chairman
Strategy and ESG Committee	1	2	66.67%	1	No
Audit Committee	5	2	66.67%	1	Yes
Nomination Committee	0	2	66.67%	1	Yes
Remuneration and Appraisal Committee	2	2	66.67%	1	Yes



Board Diversity and Composition

In 2025, the Board of Directors comprised **9** members. Board members bring expertise across economics, management, biomedical sciences and other disciplines. Their diverse professional backgrounds and extensive industry experience ensure that company decisions are scientifically sound and forward-looking.



Independence of Board of Directors

Jafron emphasizes the critical role of independent directors in corporate governance. Through institutionalized processes, we leverage their expertise to enhance board oversight and decision-making quality. We've established an Independent Director Committee and formulated the *Work Rules of Independent Directors* and the *Work Rules for Independent Director Annual Reporting*, ensuring that **3** qualified independent directors, accounting for **1/3** of the board, are appointed in compliance with regulatory requirements.

Key Performance

During the Reporting Period, the Company convened **7** special meetings of independent directors, at which **18** proposals were reviewed and approved.

Management of Remuneration for Directors and Senior Management

Jafron has established the *Remuneration Management System for Directors and Senior Management* and the *Rules of Procedure for the Remuneration and Appraisal Committee under the Board of Directors*. This framework ensures that remuneration management is closely aligned with the Company's strategic objectives and performance outcomes. The Remuneration and Appraisal Committee scientifically designs remuneration structures, reasonably determines compensation levels, and strengthens the linkage between remuneration, long-term performance and risk management. This ensures that remuneration arrangements are aligned with the Company's long-term development strategy and the overall interests of shareholders.

Independent directors receive fixed allowances determined based on the Company's operational circumstances, applicable regulatory requirements, and benchmarking against comparable listed companies. The remuneration of non-independent directors and senior management is linked to their respective managerial responsibilities, benchmarked against comparable positions in the same industry and region, and determined based on annual performance evaluation results. Jafron continues to optimize its remuneration decision-making processes and enhance disclosure transparency, thereby strengthening compliance and credibility in remuneration governance, encouraging diligence and accountability among senior management, and supporting the Company's sustainable and high-quality development.

Investor Relations Management and Shareholders' Rights and Interests

Information Disclosure

Jafron strictly complies with the Measures for the *Administration of Information Disclosure by Listed Companies* and other relevant regulations. We've established the policies, such as the *Information Disclosure Management Policy*, the *Material Information Internal Reporting Procedures* and the *Accountability Mechanism for Material Errors in Annual Reports*, to optimize internal reporting and review mechanisms and ensure timely and compliant information disclosure. Through disclosure channels such as the Shenzhen Stock Exchange website, we proactively communicate the Company's operating results, governance practices and development strategy, effectively safeguarding investors' right to information and participation, particularly those of minority shareholders. We're committed to building an open, transparent and trust-based investor relations framework, while maintaining a strong and credible capital markets reputation. In the Shenzhen Stock Exchange information disclosure assessment for 2024–2025, Jafron was awarded an "A (Excellent)" rating.

Key Performance

During the reporting period, the Company issued **154** interim reports and **4** periodic reports, with no regulatory penalties arising from information disclosure violations.

Investor Relations Management

At Jafron, we highly value investor relations. In line with the *Guidelines for Investor Relations Management of Listed Companies*, the *Rules Governing the Listing of Stocks on the ChiNext Market of Shenzhen Stock Exchange* and other relevant laws and regulations, we have established the *Investor Relations Management Policy* to regulate investor relations management. Through various channels, including the SZSE Cninfo Platform, performance briefings, investor hotlines, and shareholders' meetings, we continuously strengthen communication with investors and actively convey our business strategies, management initiatives, and achievements to enhance investors' understanding and recognition of the Company.

Communication with Investors in 2025


Number of Investor Receptions	5 Times	Number of On-Site Investor Surveys Received	2 Times
Total Performance Briefings Convened	3 Times	Total number of investor inquiries via irm.cninfo.com.cn.	89 Times
Number of Investor Questions answered on the Cninfo Platform	72 Questions		

Return to Shareholders

According to the profit distribution policy stipulated in the *Articles of Association*, the Company has formulated scientific and effective profit distribution decision-making procedures and adjustment mechanisms to ensure that the entire distribution process is open and transparent, to fully safeguard minority shareholders' right to information and participation and effectively safeguard their legitimate rights and interests.

Jafron places strong emphasis on shareholder returns. While balancing short-term shareholder interests with long-term sustainable development, it has consistently implemented a stable cash dividend policy. Since its listing, the Company has paid dividends for **9** consecutive years, with cumulative cash dividends totaling RMB **3.571** billion.

Cash Dividends in the Past 3 Years



Protection of Creditors

To mitigate debt-related risks and effectively safeguard creditors' legitimate rights and interests, Jafron has established a suite of governance policies, including the *Management System for Raised Funds* and the *Rules of the Bondholders' Meeting for Convertible Corporate Bonds*, thereby strengthening its debt risk management framework. We strictly perform our obligations in accordance with agreements entered into with creditors. We also engage professional agencies to conduct credit ratings for both the issuer and its debt instruments, ensuring that creditors are fully informed of the Company's operating performance and bond-related risks. These measures safeguard creditors' right to information and decision-making basis, and effectively protect their lawful interests.

Key Performance

During the Reporting Period, the Company maintained an **"AA"** credit rating, and no debt default incidents occurred.

Compliant Operation and Risk Management

Compliant Operations

Jafron places strong emphasis on compliance management and continues to enhance its compliance governance framework. A Chief Compliance Officer has been appointed to coordinate compliance management, ensuring that compliance requirements are embedded throughout business processes. We've established the control objective of "strengthening internal controls, preventing risks and promoting compliance" and have developed a comprehensive, organization-wide and all-encompassing compliance risk prevention and control system. In addition, we've signed a *Legal Compliance, Integrity and Self-Discipline Commitment* with all marketing employees, clearly defining legal responsibilities and liability mechanisms for violations. This organization-wide commitment strengthens compliance accountability and promotes the deep integration of compliance principles across the entire business chain.

Guided by a compliance-oriented corporate culture, Jafron has established a multi-tiered and organization-wide compliance training system. Through regular training programs, employees are guided to strictly adhere to compliance boundaries and professional ethics, fostering a culture in which compliance is observed by all and rules are followed in all operations.



Hubei Jafron Compliance Training



Beijing Jafron Compliance Training

Risk Management

Jafron strictly complies with applicable laws and regulations and actively implements comprehensive risk management practices. We exercise end-to-end control over core business segments, promptly identifying and assessing operational risks, and continuously monitoring and improving mitigation measures for key risks closely related to our operations, including investment, business, operational and sustainability-related risks. These efforts further enhance the Company's risk prevention and control capabilities.

In addition, the Company has formulated systems such as the *Public Opinion Management System*, established rapid response and emergency handling mechanisms, and promptly and appropriately addressed various situations that may affect the Company's share price, business reputation, and normal production and operation activities, thereby maintaining stable operations and effectively protecting the legitimate rights and interests of investors.

Internal Control

In strict accordance with the requirements of laws and regulations such as the *Basic Norms for Enterprise Internal Control*, and in light of actual operational and management conditions, the Company has formulated and improved special systems including the *Internal Audit Management System* and the *Internal Audit Work System*. These systems further standardize internal audit workflows, strengthen the effectiveness of internal oversight, effectively prevent operational risks, and tangibly enhance corporate governance standards and internal control execution capabilities. We've established a Legal Audit and Supervision Center responsible for internal audit functions, including annual audit planning, implementation of internal audit activities, and organization of audit projects. This strengthens internal control and helps prevent operational risks.

During the reporting period, the Legal Audit and Supervision Center conducted independent audits of key business processes, financial reporting and internal control effectiveness, issuing a total of **17** internal audit reports.

Related-Party Transactions

Jafron strictly complies with applicable laws, regulations and regulatory requirements, and has formulated the *Related Party Transaction Management Policy* and the *Special Policy for Preventing Fund Embezzlement by the Controlling Shareholders and Their Related Parties*. These policies clearly define pricing principles, decision-making procedures and information disclosure requirements for related party transactions, and regulate capital flows between the Company and its controlling shareholders, de facto controllers and related parties. This effectively mitigates risks such as benefit transfer and misappropriation of funds. During the reporting period, all related party transactions were conducted in the ordinary course of business operations, with no circumstances that impaired the lawful rights and interests of the Company or its shareholders.

Tax Management

Jafron strictly complies with the *Enterprise Income Tax Law of the People's Republic of China*, the *Law of the People's Republic of China on the Administration of Tax Collection* and other relevant tax regulations. We proactively fulfill our tax obligations and conduct tax filing, payment and planning in a standardized manner. Regular internal tax self-inspections and external audits are carried out to effectively prevent tax-related risks and avoid potential legal liabilities and economic losses arising from non-compliance. In 2025, the Company paid a total of RMB **402** million in various taxes in full compliance with the law.



Business Ethics


Anti-Commercial Bribery and Anti-Corruption

Jafron strictly complies with applicable laws and regulations, including the *Interim Provisions on the Prohibition of Commercial Bribery* and the *Guidelines for Pharmaceutical Companies to Prevent Commercial Bribery Risks* and has established and continuously improved its business ethics and anti-corruption management system to comprehensively strengthen ethical safeguards. Internally, all procurement personnel are required to sign the Integrity Commitment. Externally, we issue Integrity Notifications to all bidding entities, comprehensively advancing anti-bribery and anti-corruption efforts.

During the reporting period, the Company achieved a **100%** compliance rate in signing ethics-related declarations. There were no reported incidents involving material violations of ethical business conduct, no cases of corruption, and no litigation related to bribery.

Training on Anti-Corruption

Jafron continues to strengthen anti-corruption communication and education and actively promotes integrity culture development. Through multi-level training sessions covering anti-corruption regulations, anti-bribery systems and analysis of representative cases, the Company effectively enhances employees' compliance awareness and strengthens disciplinary safeguards for high-quality development.



Anti-Unfair Competition

Jafron strictly complies with the *Anti-Monopoly Law of the People's Republic of China*, the *Anti-Unfair Competition Law of the People's Republic of China*, and other relevant laws and regulations. We're committed to maintaining a fair and orderly market environment and prohibit unfair competitive practices such as unreasonable restrictions on partners, discriminatory treatment, and infringement of trade secrets. We strive to promote a fairer and more transparent competitive landscape. We require our suppliers to sign the *Suppliers' Integrity Agreement* and the *Non-Disclosure Agreement*, affirming their commitment to safeguarding commercial and technological secrets shared during cooperation. During the Reporting Period, no violations such as unfair competition occurred in the Company.

Appeals and Whistleblowing Mechanism

Jafron has established and implemented the *Internal Reporting and Whistleblowing Management System*, providing multiple reporting channels including mail, email and telephone, and actively accepts internal and external supervision and reports. The Group's Audit and Supervision Department is responsible for receiving, investigating and handling reported matters. We strictly protect whistleblowers' identities and personal information and ensure data security. Whistleblowers whose reports are verified and who contribute to risk prevention or loss recovery are rewarded in accordance with relevant policies.

Whistleblowing Hotline: 0756-3619947 Whistleblowing email: shenjijiancha@jafron.com

Advancing Green Transformation to Enable Sustainable Healthcare

Jafron is committed to embedding green development principles across its operations. The Company strictly complies with applicable environmental laws, regulations and industry standards, and has established a structured and continuously evolving environmental management system. We actively promote cleaner production and green manufacturing practices, with a focus on minimizing resource consumption and reducing emissions at source.

By increasing investment in environmental protection technologies, optimizing manufacturing processes and expanding the use of clean energy and renewable materials, we continue to improve resource efficiency and environmental performance. At the same time, we strengthen organization-wide environmental awareness and promote green office practices and low-carbon mobility to foster a culture of shared responsibility for sustainability.

ESG Material Topics Covered in this Chapter

- Environmental Compliance Management
- Energy Utilization
- Response to Climate Change
- Circular Economy
- Pollutant Emissions
- Waste Disposal
- Water Resource Utilization
- Ecosystem and Biodiversity Protection

SDGs Responded in this Chapter



Response to Climate Change

Jafron proactively addresses climate-related risks and opportunities by enhancing its climate governance framework and integrating climate considerations into strategic planning. Through the implementation of structured and science-based management measures, we seek to reduce greenhouse gas emissions. In alignment with the Recommendations of the Task Force on Climate-related Financial Disclosures (TCFD), we manage and disclose climate-related matters across four key dimensions—governance, strategy, risk management, and metrics and targets—providing a robust framework to guide ongoing climate action.

Governance

Building on its overall sustainability governance structure, Jafron has established a dedicated climate governance framework to ensure systematic and standardized management of climate-related initiatives. The Strategy and ESG Committee under the Board of Directors serves as the central decision-making body, overseeing climate-related matters and other sustainability priorities, and approving strategic direction, implementation pathways and control mechanisms. This ensures that climate governance is fully aligned with the Company's development strategy. Relevant subsidiaries and functional departments operate within a coordinated execution framework, implementing energy efficiency, pollution reduction and carbon mitigation initiatives according to their respective responsibilities. Through end-to-end operational controls, we effectively fulfill our climate responsibilities, contribute to climate change mitigation, and advance green, low-carbon, high-quality development.

Strategy

Based on its operational needs, Jafron systematically identifies climate-related risks and opportunities linked to its business activities, and assesses their potential time horizons and financial implications. By establishing a structured climate response framework, we continue to strengthen the Company's climate risk management capabilities and overall sustainability performance.

Risk Type	Description of Risk	Impact Duration	Potential Financial Impact	Countermeasures
Physical Risks	Acute Risk Extreme weather events such as typhoons, floods, earthquakes and blizzards can cause significant damage to equipment and power outages, which may in turn disrupt production processes.	Short term	Increase in operating costs and decrease in operating revenue	<ul style="list-style-type: none"> Establish emergency response systems for extreme weather; pre-deploy protective equipment and emergency supplies to strengthen emergency response capabilities; Install energy storage solutions to manage power outages, and develop emergency power outage plans; Strengthen infrastructure construction to improve resilience against natural disasters.
	Chronic Risks Rising global temperatures may lead to increased energy consumption for cooling and refrigeration systems, thus driving up energy costs and potentially causing equipment damage. Temperature fluctuations may affect product manufacturing and storage, necessitating enhanced temperature control systems that add to operating costs.	Long term		<ul style="list-style-type: none"> Develop energy-saving management policies and integrate advanced energy management systems to improve energy efficiency; Deploy photovoltaic energy systems in production facilities to optimize the energy mix.

Risk Type	Description of Risk	Impact Duration	Potential Financial Impact	Countermeasures
Transition Risks	Policy Compliance Risk As climate change policies continue to evolve, failure to develop and implement strategies aligned with these regulations may expose the Company to compliance risks.	Short and medium term	Increase in compliance and operating costs	<ul style="list-style-type: none"> Monitor and analyze national and regional climate-related regulations to ensure the Company remains compliant with the latest environmental laws and regulations
	Technology Risks As the Company advances technology R&D, equipment upgrades and process optimization in response to decarbonization trends, failure to align with low-carbon transition requirements may weaken product competitiveness and result in loss of market share.	Medium term	Increase in production costs and R&D expenditures	<ul style="list-style-type: none"> Implement energy efficiency retrofit projects; Perform thorough evaluations before launching new projects or investing in new technologies.
	Market Risk Growing customer and market preference for low-carbon and environmentally sustainable products, coupled with potential increases in upstream raw material costs driven by climate-related factors.	Medium term	Decrease in production costs and operating revenue	<ul style="list-style-type: none"> Invest in the development of low-carbon, environmentally-friendly products; Adjust procurement strategies dynamically based on market trends.
	Reputation Risks Stakeholders' growing interest in green development could damage the Company's reputation if we fail to meet their expectations.	Short and medium term	Reputation and revenue loss	<ul style="list-style-type: none"> Prioritize ESG management and practices, ensuring timely disclosure of climate-related initiatives and performance; Build a strong green brand image, reducing carbon emissions to meet stakeholder expectations.

Opportunity Type	Description of Opportunity	Impact Duration	Potential Financial Impact	Countermeasures
Product and Service Opportunities	Climate change has driven growing demand for low-carbon, environmentally responsible products. By developing eco-friendly medical products and enhancing product performance, the Company is well-positioned to respond to evolving market demands, boost brand image, strengthen its competitive advantage and expand revenue streams.	Medium to long term	Market premium and revenue growth	<ul style="list-style-type: none"> Advance green product certification in alignment with European Green Deal requirements and domestic environmental standards to support international market expansion; Enhance marketing initiatives to emphasize products' low-carbon attributes and align with hospitals' green procurement requirements.
Resource Efficiency Opportunities	Optimizing production processes and adopting high-efficiency equipment or energy management systems can significantly enhance resource utilization, lower operational costs, and reduce carbon emissions.	Short and medium term	Reduced production costs and improved gross margins	<ul style="list-style-type: none"> Optimize hemoperfusion cartridge production processes to minimize material waste; Implement waste segregation, recycling and circular utilization practices; Deploy energy-efficient production and sterilization equipment, alongside advanced energy management systems.


Opportunity Type	Description of Opportunit	Impact Duration	Potential Financial Impact	Countermeasures
Market Opportunities	Ongoing enhancements in domestic and international low-carbon policy frameworks, coupled with increased support for green healthcare and low-carbon industries, are creating new growth opportunities. At the same time, rising demand for green collaboration across the industry enables the Company to leverage policy incentives and ecosystem partnerships to expand its market presence.	Medium to long term	Reduced financing pressure and increased revenue	<ul style="list-style-type: none"> Strengthen collaboration with academic institutions and industry leaders to establish low-carbon R&D platforms; Actively participate in the development of green standards and industry exchanges within the medical device sector, promoting the Company's low-carbon strategy and practices.

Note: Impact Duration: refers to the different periods when different climate-related risks and opportunities will affect the Company. The Company categorizes the impact duration into short term (0-1 year), medium term (1-5 years), and long term (over 5 years).

Impact, Risk, and Opportunity Management


To systematically identify and manage climate-related risks and opportunities, Jafron has integrated climate-related risks into its organization-wide risk management process. This process spans the full lifecycle from risk identification to response planning and implementation. Through continuous monitoring and periodic review, we ensure timely, proactive responses to evolving climate-related risks and opportunities.

Management Process



Metrics and Targets

To strengthen climate governance, Jafron has incorporated greenhouse gas (GHG) emissions as a key performance indicator for managing climate-related risks, in alignment with its operational profile. These metrics are regularly monitored and benchmarked against established targets, with ongoing refinement of management measures to support the Company's low-carbon transition and contribute to China's carbon peaking and carbon neutrality goals.



Environmental Compliance Management

Jafron strictly complies with the *Environmental Protection Law of the People's Republic of China* and other applicable environmental laws and regulations. We continue to enhance our environmental management system, rigorously control pollutant generation and emissions, and systematically improve environmental performance. We are committed to maintaining a clean, safe and healthy operating environment, and to achieving high-quality development in harmony with ecological protection.

Environmental Management System

Jafron has established the *Environmental Management Policy*, underpinned by clearly defined roles, responsibilities and tiered accountability. The Environmental, Health and Safety (EHS) Department serves as the central coordinating body, overseeing organization-wide pollutant discharge monitoring, inspection and compliance management. It conducts regular environmental risk assessments, provides technical guidance to business units, and leads critical activities including environmental impact assessments (EIA), project completion acceptance, and the development of emergency response plans. The department also manages key functions such as solid waste disposal, routine environmental monitoring and regulatory compliance inspections. Each business unit is required to designate dedicated environmental management personnel responsible for the independent execution of environmental management activities. This ensures compliant discharge of wastewater, air emissions and solid waste, as well as the standardized operation of environmental protection facilities. Core responsibilities—including EIA acceptance, self-monitoring, and compliance evaluation—are effectively implemented to support environmental compliance and sustainable operations. To reinforce environmental governance, we've established a structured supervision and performance evaluation mechanism. Regular, multi-dimensional audits and inspections are conducted, with performance outcomes linked to incentive and accountability measures.

During the reporting period, the Company continued to strengthen its environmental management practices, with total environmental protection investment amounting to RMB 2.288 million. And we did not incur any administrative penalties for violations of environmental laws or regulations, nor were there any material environmental risks or adverse environmental impacts.

Environmental Compliance Targets	Achievements in 2025
Environmental Pollution Incidents: 0	✔ Achieved
Administrative Penalties Related to EHS Matters: 0	✔ Achieved

Management of Environmental Risks

Environmental Impact Assessment

Jafron places strong emphasis on mitigating the potential impacts of pollutant emissions on employee health and the surrounding environment. All existing operations and new construction projects are subject to environmental impact assessments (EIA) in strict accordance with applicable regulatory requirements. During the EIA process, potential environmental risks—including wastewater, solid waste and other emissions—are systematically identified and controlled. Environmental compliance, along with energy efficiency and carbon reduction performance, is incorporated as a key criterion in project feasibility assessments. This ensures that all projects are developed and operated in a compliant, environmentally responsible and sustainable manner throughout their lifecycle.

During the reporting period, the Company completed and obtained regulatory approval for the EIA reports of the Workshop #10 Expansion Project, the North Zone Expansion Project of the Medical Device Company, and the Jafron Blood Purification Jinding Project.

Environmental Self-Inspection

Jafron complies with national and local regulatory requirements on pollutant discharge and regularly engages qualified third-party agencies to monitor air emissions, wastewater and noise levels at its facilities. This ensures that all emission sources meet applicable standards and that environmental impacts are effectively mitigated. During the Reporting Period, no emission non-compliance incidents occurred in the Company.

Emergency Management

Jafron places a high priority on emergency management for environmental incidents. We've developed the *Contingency Plan for Environmental Emergencies* and established a comprehensive environmental emergency management framework, clearly defining the organizational structure, response procedures and allocation of responsibilities. We conduct regular environmental emergency response drills to continuously strengthen our emergency response and on-site incident handling capabilities, ensuring that in the event of an environmental incident, response protocols can be promptly activated to contain pollutant dispersion and minimize environmental impact. We also continuously enhance our risk prevention and emergency preparedness mechanisms, safeguarding ecological security and ensuring safe, stable and compliant operations. During the Reporting Period, the Company conducted **6** emergency response drills for environmental incidents.

Identification of Potential Hazards

Jafron proactively identifies and manages environmental risks by establishing a normalized mechanism for hazard identification and remediation. Regular inspections, risk assessments and closed-loop corrective actions are implemented throughout the entire production and operational process. Key focus areas include wastewater, air emissions, hazardous waste management, and the operation of environmental protection facilities. Through continuous refinement of inspection standards, clear assignment of responsibilities and timely rectification of identified issues, the Company strengthens its environmental risk management capabilities and ensures compliant operations and ecological safety. During the reporting period, the Company submitted **11** assessment results through the Environmental Emergency Regulatory System of Guangdong Province. All assessments confirmed the absence of any environmental hazards.

Training on and Promotion of Environmental Protection

To strengthen the environmental awareness and capabilities of EHS personnel at all levels, the Company conducted thematic training sessions, knowledge-sharing workshops, hands-on operational practice and corresponding evaluations—helping to ensure our EHS personnel can effectively fulfill their responsibilities and support the Company's compliance objectives and EHS efforts.

Key Performance

During the Reporting Period, the Company offered **10** training sessions on environmental protection for **80** (person-times) participants, with a total duration of **60** hours.

Upholding Compliance, Strengthening Environmental Foundations – Specialized Training on Corporate Environmental Protection and Waste Disposal Compliance Management

Case

In April 2025, to thoroughly implement laws and regulations related to ecological and environmental protection, prevent risks of environmental violations, and ensure the company's lawful and compliant operations, Jafron organized a specialized training on environmental protection and waste disposal compliance management. This training focused on the core requirements of corporate environmental compliance and standardized pollutant disposal practices. Delivered through a three-dimensional approach of "policy interpretation + case-based education + practical guidance", the training equipped all participants with the skills of compliant waste disposal and integrated the compliance mindset across the entire production and operational process.





Wastewater and Waste Emissions Management

Jafron strictly complies with the *Law of the People's Republic of China on Prevention and Control of Water Pollution*, the *Law of the People's Republic of China on Prevention and Control of Atmospheric Pollution* and the *Law of the People's Republic of China on the Prevention and Control of Environmental Pollution Caused by Solid Wastes*, and relevant local regulations such as the *Guangdong Regulations on Solid Waste Pollution Prevention and Control*. We've established a comprehensive pollution and waste management system and completed the registration of fixed pollution sources for regulatory oversight. At the same time, we actively implement measures to reduce wastewater, air emissions and solid waste generation, with the objective of minimizing the environmental footprint of business operations.

Management of Waste Gases



Jafron adheres strictly to national regulatory requirements, including the *Law of the People's Republic of China on Prevention and Control of Atmospheric Pollution* and the *Emission Standard of Air Pollutants for Boilers*, and has defined clear responsibilities, procedures and monitoring requirements for air emissions management.

Targeted treatment measures are applied based on emission sources: Process emissions are treated through a three-stage system comprising activated carbon adsorption, alkaline scrubbing and water scrubbing prior to discharge. Wastewater treatment plant emissions are treated using a combined process of alkaline scrubbing, activated carbon adsorption and UV photolysis to ensure compliance with discharge standards. These measures effectively control atmospheric pollutant emissions and contribute to the protection of ambient air quality.



Wastewater Management


The Company's wastewater primarily consists of domestic sewage and industrial effluent. We've established a closed-loop, full-process wastewater management system. We strictly implement a rainwater-sewage separation system to prevent soil and environmental contamination. Depending on wastewater characteristics, treatment is conducted through a multi-stage process comprising iron-carbon treatment, acid-base neutralization, anaerobic treatment, aerobic treatment, sedimentation and MBR membrane filtration. Special wastewater streams are collected, classified and treated separately in accordance with regulatory requirements. The Wastewater Treatment Management Department maintains comprehensive operational records, including treatment logs, facility operation and maintenance records, and routine monitoring data, ensuring stable compliance with discharge standards. During the Reporting Period, all wastewater discharged by the Company met applicable standards.




Waste Treatment

Jafron adheres to the principles of waste minimization, segregation and resource recovery in its waste management practices. Waste is classified into general waste and hazardous waste, with differentiated handling and disposal measures applied to each category. All operating units are required to sort, collect and store waste in accordance with established procedures.

During the Reporting Period, the Company achieved a **100%** compliance rate in waste disposal.





Noise Management

Jafron has established a full-process noise pollution prevention and control system. All operating units strictly comply with applicable noise emission limits and implement lifecycle management and mitigation measures for noise-generating facilities to minimize environmental impact. For high-noise operations, source-level mitigation is implemented through equipment selection, process optimization and engineering controls. Noise monitoring is conducted prior to commissioning new equipment; where excessive emissions are identified, corrective actions or noise reduction measures are implemented without delay.


Resource Utilization

Jafron prioritizes efficient and intensive resource utilization as a core element of its green operations strategy. We continuously improve energy efficiency through optimization of the Company's energy structure, enhance water-use efficiency through the deployment of water-saving technologies, and strengthen lifecycle management of materials. Through the promotion of material reduction, recycling and circular utilization, we've established a science-based and efficient resource management model, strengthening the foundation for sustainable development and accelerating the transition toward a low-carbon operating model.

Energy Utilization


Jafron strictly complies with the *Energy Conservation Law of the People's Republic of China*, the *Renewable Energy Law of the People's Republic of China*, and other applicable laws and regulations. We've established a suite of internal policies, including the *Regulations on Energy Conservation Management*, the *Cost Control Guidelines for Manufacturing Division I*, and the *Lean Management Measures for Workshop #1*. These frameworks strengthen full-process energy management and promote efficient and circular utilization of energy resources. The Company's energy consumption is primarily associated with production operations and administrative support activities, and includes electricity supplied by the grid and purchased natural gas.

In addition, we've established a dedicated Energy Conservation Office staffed with certified energy managers, supported by a technical advisory group and an energy-saving task force. This office centrally coordinates energy management across the organization. The office conducts annual energy efficiency performance assessments, regularly monitors energy wastage, and investigates and addresses non-compliance, thereby strengthening overall energy governance.



Energy Conservation and Emission Reduction Measures


Jafron continues to advance energy efficiency through technological upgrading. We've introduced high-efficiency production equipment and implemented waste heat recovery systems to improve overall energy utilization. In addition, a power energy management system has been deployed to enable real-time monitoring of energy consumption data, supporting continuous optimization of energy use and reduction in unit energy intensity. We also implement targeted energy-saving initiatives to further reduce energy consumption.



Energy Efficiency Retrofit Project for Pump Systems in Power Station

Case

Jafron implemented an energy efficiency retrofit for pump systems in its power station. While maintaining stable chilled water system operating conditions, four 55kW pumps were replaced with 37kW energy-efficient pumps, supplemented with booster devices. The project is expected to achieve electricity savings of over 25% per pump, generate annual electricity cost savings of approximately RMB 370,000, and deliver a static payback period of approximately 1.62 years. The Company plans to pilot the initiative in facilities with lower operating pressure before gradually expanding implementation to headquarters facilities, balancing energy efficiency improvements with operational safety.



Jafron continues to advance the adoption of clean energy. Photovoltaic (PV) power generation systems have been installed across its facilities to partially replace conventional electricity consumption and reduce dependence on fossil fuels. In addition, we are exploring the use of cleaner energy sources, such as natural gas, to optimize the energy mix and reduce carbon emissions from production activities.

Rooftop Photovoltaic Power Generation at the Plant Area

Case

Jafron has developed rooftop PV power generation systems at its Jinding facility, Northern District facility and headquarters facility in the Zhuhai National High-Tech Industrial Development Zone, Guangdong Province. The project integrates rooftop resources across the three sites and optimizes PV module layout, achieving a total installed capacity of 1,849.65 kW. Leveraging favorable solar irradiation conditions in Zhuhai, the PV system operates efficiently and reliably, generating approximately 2.0823 million kWh of electricity in 2025. All generated electricity is used for on-site production and office operations, significantly reducing reliance on grid power. The project is expected to reduce electricity costs by approximately RMB 353,300 and further supports the Company's transition toward low-carbon and sustainable development.




Energy Conservation Awareness Development

Jafron conducts dedicated training programs and awareness campaigns on energy conservation and emissions reduction. These campaigns cover energy management principles and practical operational skills, with the objective of strengthening employees' energy efficiency awareness and execution capability. Participants primarily include employees in key production and operational roles. Through systematic training, the Company further enhances its overall energy conservation and emissions reduction performance.

Training on Refined Energy Management for Workshop #1

Case

To fully tap energy-saving potential and implement refined management, Workshop #1 recently held a specialized training program on energy management. The training, tailored to production realities, provided a detailed explanation of key measures such as pre-cooling and peak-shaving operation of chillers, low-frequency control of air-conditioning systems, precise air supply by compressors, and utilization of steam waste heat. Through case analysis and hands-on demonstrations, employees were guided to start with small actions, strictly follow equipment startup and shut-down procedures and leak inspection protocols, and integrate energy conservation and consumption reduction into daily operations, supporting the workshop's green and efficient performance.



Water Resource Utilization

Jafron recognizes the critical importance of water resources and strictly complies with the *Water Law of the People's Republic of China* and other applicable laws and regulations in managing water use. In terms of water sourcing, water required for production and operations is primarily supplied by municipal systems, ensuring standardized water intake management at the source and eliminating unauthorized or wasteful consumption.

To further improve water-use efficiency and fulfill its water-saving responsibilities, the Company proactively adopts advanced water-saving technologies and high-efficiency equipment produced at home and abroad. In line with the characteristics of biopharmaceutical and medical device manufacturing processes, it has comprehensively optimized water usage across production stages to further unlock water-saving potential.

Recycling of Water Distiller Cooling Water to Enable Water Circularity

Case

Jafron has optimized the operating process of water distillers by collecting cooling water generated during operation, filtering and purifying it, and reusing it for equipment cooling. This reduces direct discharge of cooling water, lowers freshwater consumption, and effectively integrates water conservation principles into daily production processes, thereby improving overall water resource efficiency.



In addition, Jafron places strong emphasis on enhancing employees' water conservation awareness. Regular training programs are conducted to promote water-saving regulations, technologies and best practices, fostering a corporate culture of "saving, valuing and protecting water resources, with enterprises taking the lead by example". Employees are actively encouraged to participate in water-saving initiatives, translating awareness into concrete actions and supporting the development of a water-efficient society. During the reporting period, the Company was recognized as a Water-Saving Enterprise.

2025 Indicator

Total Water Consumption

538,030 Ton

Total Freshwater Withdrawal

483,152 Ton

Volume of Recycled and Reused Water

54,878 Ton

Proportion of Recycled and Reused Water

10.20%


Material Utilization

The materials used in the Company's production and operations primarily include raw and auxiliary materials, as well as paper- and plastic-based packaging materials. To achieve standardized and structured material management, Jafron has established a series of internal policies and procedures, including the *Raw and Auxiliary Materials Inbound and Outbound Control Procedures*, the *Automated Warehouse Material Handling Procedures*, and the *Raw Material Sorting and Automated Handling Buffer Operating Procedures*. These systems ensure that all material flows are governed by standardized requirements and controlled processes.

Across the full material lifecycle, we implement refined management at each stage. This includes procurement and acceptance of raw and auxiliary materials and packaging materials; classified storage, environmental monitoring and labeling after warehousing; transportation planning and protection measures; as well as approval controls and quota management for material requisition. These measures ensure robust material quality control at source, support efficient and orderly production operations, and reduce material waste through disciplined lifecycle management.

In addition, guided by the principles of efficiency enhancement, cost optimization and green development, we implement a series of packaging optimization initiatives, including material reduction, lightweight design and circular utilization, while ensuring compliance with required protective performance standards. These measures effectively reduce packaging material consumption costs and improve material circularity. We also actively explore the application of green manufacturing processes across production, testing and other operational stages to reduce material usage and further embed sustainable manufacturing practices.

Green Packaging Initiatives	
Category	Specific Actions



Application of Hollow Fiber Membrane Sub-Assemblies

Case

During the reporting period, Jafron adopted a simplified encapsulation process (polypropylene tubes and AB adhesive) to fabricate compact membrane sub-assemblies for direct ultrafiltration and screening performance testing. Compared with the traditional approach of producing complete hemodialyzers and conducting testing in accordance with YY0053 standards, this method significantly reduces material consumption and testing costs, enabling a more efficient and cost-effective evaluation of membrane performance.



Comparison of Hemodialyzer and Sub-assembly Appearance

2025 Indicator



Total Use of Packaging Materials	Consumption of Paper Packaging Materials	Consumption of Plastic Packaging Materials	Quantity of Packaging Materials Recycled
5,114.62 Ton	4,947.75 Ton	166.87 Ton	28.84 Ton

Green Office

Jafron actively promotes green office practices and advocates paperless operations. Employees are encouraged to prioritize digital workflows and electronic documentation, thereby effectively reducing paper consumption and resource waste. In parallel, we continue to expand the use of energy-efficient office equipment, including energy-saving lighting systems, low-power printers and energy-efficient computers, to reduce overall office energy consumption. Through these green office initiatives, we continuously improve resource efficiency and foster a low-carbon, environmentally friendly and high-efficiency working environment, supporting the Company's sustainable development.

Ecosystem and Biodiversity Protection

Jafron integrates green development principles throughout its R&D and manufacturing processes, reducing environmental impact through cleaner production processes and energy-saving initiatives, and safeguarding the sustainable use of natural resources at source. In its operations, the Company strictly complies with environmental regulations and promotes waste recycling and resource recovery to minimize impacts on surrounding ecosystems. Employees are encouraged to participate in environmental public welfare activities, contributing to biodiversity protection through practical engagement. Looking ahead, we will continue to advance green innovation and are committed to achieving harmonious coexistence between business development and ecological protection, contributing to the goal of building a community of all life on Earth.


Building a Harmonious Workplace through People-Oriented Development

Jafron strictly adheres to international labor standards as well as applicable laws and regulations, safeguarding equal employment opportunities, equitable career development, and occupational health and safety, while firmly prohibiting all forms of discrimination and unfair treatment. We've established diversified and inclusive communication platforms, strengthened labor dispute mediation mechanisms and maintained accessible employee grievance channels to ensure employees' voices are heard in a timely manner, enabling every employee to receive respect and care in the workplace. In parallel, we actively fulfill our social responsibilities and promote coordinated development among the enterprise, employees, communities and society, fostering shared value creation through a people-centered approach and contributing to a harmonious and inclusive ecosystem.

ESG Material Topics Covered in this Chapter

- Employee Training and Development
- Occupational Health and Safety
- Social Contribution
- Rural Revitalization
- Due Diligence
- Protection of Employees' Legal Rights and Interests
- Access to Healthcare

SDGs Responed in this Chapter



Protection of Employees' Rights and Interests


Jafron upholds a people-oriented management philosophy and strictly complies with the *Labor Law of the People's Republic of China* and the *Labor Contract Law of the People's Republic of China*. We've established a comprehensive human resources management system and internal control framework, ensuring full implementation of labor contract management, employee training and development, compensation and benefits, rest and leave entitlements, and occupational health protection. These measures effectively safeguard employees' legitimate rights and interests and support the creation of a safe, respectful and equitable working environment.

Talent Recruitment

Adhering to the principles of openness, fairness and merit-based selection, Jafron has established a standardized and compliant recruitment system. All candidates are provided equal opportunities without discrimination based on gender, ethnicity, religion or referral source. We've formulated the *Recruitment Management Policy*, the *Regulations on Employee Position Transfer Management* and the *Internship Management Regulations*, which clearly define recruitment and interview procedures and provide standardized guidance for hiring activities. All recruitment processes strictly comply with applicable national labor laws and regulations. We firmly prohibit child labor and forced labor, and ensure lawful and compliant employment practices.

Employee Composition

As of the end of the Reporting Period, the Company had a total of **2,301** employees.



Recruitment Channels

Jafron has established a diversified talent acquisition system integrating social recruitment, campus recruitment and internal referral mechanisms. Social recruitment leverages leading online recruitment platforms to precisely access high-quality industry talent. Campus recruitment is conducted through long-term, reliable partnerships with multiple universities across China, including on-site presentations and outreach activities, to attract outstanding graduates and build a sustainable pipeline of young talent to support long-term development.

As of the end of the Reporting Period, the Company had a total of **295** newly recruited employees.

Diversity, Equality, and Inclusion

We champion diversity, equity and inclusion as core values of our corporate culture. We are committed to creating a workplace that respects individual differences and ensures equal opportunity regardless of ethnicity, race, gender or religious belief. Every employee is treated with dignity and fairness.

DEI (Diversity, Equity and Inclusion) Practices and Key Performance Indicators

- Jafron fully respects ethnic diversity. As of the end of the reporting period, we employed **85** ethnic minority employees, accounting for approximately **4%** of the total workforce. Ethnic minority employees have become an important and integral part of the Company's development.
- Jafron actively fulfills its social responsibility by supporting employment opportunities for persons with disabilities. As of the end of the reporting period, we employed **6** employees with disabilities.

Anti-Discrimination and Anti-Harassment

Jafron is firmly committed to fostering an equal and inclusive corporate culture. We explicitly prohibit any form of discrimination throughout all employment processes, including recruitment, hiring, compensation, promotion and performance evaluation, on the basis of gender, age, education, ethnicity or physical condition. We also strictly prohibit any form of workplace harassment, including verbal, physical and online harassment. Clear definitions of non-compliant behaviors and corresponding disciplinary measures have been established to ensure effective enforcement, safeguarding the dignity and legitimate interests of all employees.

Protection of Female Employees' Rights and Interests

Jafron places strong emphasis on safeguarding the rights and interests of female employees, and has established a robust system to protect female employees' rights and interests in strict compliance with the *Special Provisions on Labor Protection for Female Employees* and other applicable laws and regulations. In accordance with legal requirements, we implement comprehensive occupational protections for female employees during menstruation, pregnancy, childbirth and breastfeeding. Work arrangements and job assignments are reasonably adjusted to eliminate gender discrimination and any form of unreasonable employment requirements. We've established a dedicated care mechanism for female employees and regularly provide psychological counseling services, including on-site professional counseling support, to safeguard employees' physical and mental well-being. In addition, a range of welfare facilities has been established, including lactation rooms, women's rest lounges and "Care Rooms for Moms", ensuring female employees receive comprehensive workplace care and support.

Key Performance

Proportion of Female Employees in Management	24%	Employees Taking Maternity Leave	91 persons	Return Rate of Employees on Maternity Leave	100%
Employees who took parental leave	48 persons	Return-to-work rate post-parental leave	100%		

Compensation and Benefit Management

Remuneration Management

Jafron has established the *Compensation Management Policy* and the *Performance Evaluation Policy*, forming a scientific and well-structured remuneration and incentive framework. Guided by the principles of distribution according to work, performance orientation, fairness and equity, we closely link compensation with job value, individual performance and competency, thereby building a market-competitive compensation structure that safeguards employees' legitimate remuneration rights. We've also introduced equity incentives to fully recognize employee contributions and value creation, motivating employee engagement and innovation through a structured incentive mechanism. This ensures alignment between employee value realization and the Company's sustainable development objectives.

Welfare Benefits

Jafron regards employee welfare as a key pillar of sustainable development and has established a comprehensive benefits system. In addition to statutory contributions to social insurance schemes and the housing provident fund, and ensuring employees' statutory leave entitlements, we provide a range of additional welfare and human-centered care measures. In strict compliance with applicable national and local regulations, we've formulated the *Attendance and Leave Management System* to standardize working hour management and safeguard work-life balance, enabling employees to share in the benefits of corporate development.


Key Performance

During the Reporting Period, the social insurance coverage rate was **100%**.


Jafron consistently places employees' physical and mental well-being as well as the workplace environment at the forefront of its priorities. Upholding a people-oriented philosophy, we provide comprehensive logistical support across office facilities, dining, accommodation, recreation and fitness and parking, fully meeting employees' diverse needs. Through the continuous optimization of management practices and workplace facilities, we are committed to creating a positive, safe and comfortable working and living environment, thereby enhancing employees' sense of fulfillment and well-being, and further strengthening corporate cohesion and engagement.




Workplace Amenities




Break Room Cafés




Dining Facilities




Dormitories



Gym



Yoga Studio



Gym

Labor Relations Management

Democratic Governance

Jafron has established a standardized employee democratic governance system, with the Employee Congress as the core mechanism. We've developed the *Democratic Management Policy*, the *Collective Bargaining Policy* and the *Union Leadership Open Office Hours Policy*. Employee congress meetings are convened in accordance with applicable laws and regulations to review and vote on major matters related to corporate operations and employees' vital interests. This ensures employees' rights to information, participation and expression are fully protected.

Jafron has established diversified and multi-channel employee communication and feedback mechanisms. We regularly conduct employee roundtables as well as online and offline surveys to systematically capture employee feedback and concerns with precision. A dedicated feedback channel, including a "President's Suggestion Box", has been established to broadly collect employees' views and recommendations regarding corporate development, management practices and operational improvements. We've implemented a closed-loop mechanism covering proposal submission, follow-up tracking and response feedback. Reasonable suggestions are actively evaluated and incorporated into practice. This mechanism enables employees to participate effectively in democratic management of the enterprise and contribute to corporate development, thereby fostering a harmonious labor relationship in which employees and the Company progress in alignment and achieve coordinated growth.

Labor Contract Management

Jafron strictly complies with the *Labor Contract Law of the People's Republic of China* and other applicable laws and regulations. We've formulated the *Labor Contract Management System* to standardize full lifecycle contract management. All stages—including contract establishment, performance, modification and termination—are conducted in strict accordance with legal and regulatory requirements. The rights and obligations of both the employer and employees are clearly defined, effectively safeguarding employees' lawful labor rights and interests.

Key Performance

During the Reporting Period, the signing rate of labor contracts was **100%**.

Labor Dispute Management

Jafron has issued the *Decision on Establishing a Trade Union Labor Law Supervision Committee* and has established a Labor Dispute Mediation Committee in accordance with applicable laws. The Committee is responsible for handling the initiation, negotiation, mediation and follow-up supervision of labor dispute resolution agreements. Through a multi-tiered dispute resolution mechanism, the Company continuously enhances its negotiation and mediation capabilities, effectively safeguarding employees' legitimate rights and interests.

In addition, we've established a formal employee complaint mechanism. Employees may submit complaints through multiple channels, including email and telephone. Dedicated personnel and responsible departments ensure timely receipt, investigation and resolution of employee concerns. All complaint information is kept strictly confidential.

Care for Employee

Assistance for Employees in Difficulty

Jafron consistently adheres to a people-oriented philosophy and places strong emphasis on supporting employees facing financial or personal difficulties. We've developed the *Employee Hardship Relief Policy* and established a standardized, institutionalized support mechanism. Through systematic identification of employee needs, we provide targeted assistance measures, including financial subsidies, material support and special relief programs, effectively helping employees overcome challenges and stabilize livelihoods.

Employee Activities

Jafron is committed to enriching employees' cultural and spiritual life and fostering a positive, collaborative, and inclusive workplace culture. A series of employee engagement initiatives is regularly organized, including the Jafron Festival, recognition ceremonies, family carnivals, New Year gala events, and sports club competitions. These activities actively encourage participation, alleviate work pressure, and strengthen team cohesion and employee belonging.

19th Jafron Festival Celebration

Case


Since 2007, Jafron has celebrated employees who have been with us for 10 years or more. In recognition of our successful restructuring and independent development, we designated the third Saturday of each July as the Jafron Festival—an employee holiday marked by festive events and cultural celebrations. Over the years, the Jafron Festival has become a key part of our corporate culture. On July 19, 2025, the Jafron Festival employee film screening event was successfully held at the Zhuhai Workers' Cultural Palace (Workers' Grand Theater). Employees collectively revisited the classic film *My Country, My Parents*. The event also included employee engagement activities such as souvenir gifts, scratch cards and lucky draw sessions. In recognition of long-term service, 134 employees with 10, 15 and 20 years of service were awarded commemorative gifts, including gold sailboats, gold coins and golden keys, respectively. Chairman & President Dong Fan personally attended the event and took commemorative photos with employees, expressing gratitude for their long-term contributions.



Training and Development

Employee Training

Jafron has established a systematic, end-to-end employee training framework, centered on the core objective of "role-based capability development and strengthening the Group's talent pipeline". A diversified training system has been developed, covering management training, professional training, onboarding training and general training. By integrating internal and external faculty, curricula and platform resources, we provide strong support for employee development and growth.



In 2025, guided by the dual priorities of "supporting business operations and developing talent", the Company steadily advanced its annual training plan. For new employee onboarding, standardized programs were implemented in an orderly manner, while course content and assessment mechanisms were continuously optimized to ensure the quality of newly recruited talent. For on-the-job training, we focused on key operational priorities and emerging topics such as AI, talent review, functional evaluation and business etiquette. Training activities were conducted across four major areas, including management-track training, secondary-level training, quality system training and project-based training, continuously enhancing the comprehensive capabilities of employees and managers and enabling organizational efficiency improvement. At the same time, we increased investment in training resource development, strengthened the internal lecturer pool, and expanded the integrated application of online platforms and external training resources, thereby continuously reinforcing foundational training support capabilities.

Key Performance

Investment in Employee Training RMB 0.3563 Million	Number of Employee Training Sessions 1,720 Sessions	Total Number of Persons Trained ¹ 2,487 Persons
Total Number of Persons Trained 48,377 Person-times	Coverage of Employee Training 98%	

Note 1: Total Number of Persons Trained includes former employees.

Company-wide Knowledge Contest

Case

Jafron organized a six-month, 12-session knowledge contest covering themes such as branding, products and current affairs. All business units actively participated, with a total of 12,219 participations. Through quiz-based competitive engagement, the initiative effectively stimulated employees' learning enthusiasm, encouraged focus on core business areas, deepened professional understanding and enhanced professional competencies.



Operational Analysis Meeting Training Program

Case

Jafron conducted three sessions of operational analysis meeting training, involving 98 participants across nine organizations. The training focused on systematic learning of "How to Conduct Effective Operational Analysis Meetings", followed by post-training practice sessions. A combined approach of training, practice, and application was adopted to strengthen implementation effectiveness.



Construction of Internal Trainer Team

Jafron places strong emphasis on the development of its internal lecturer team. Key personnel from management, technical and business functions are selected to form a professional internal trainer team. Through structured instruction in teaching methodologies, course development empowerment and tiered certification management, we've established a full lifecycle mechanism covering selection, development, utilization and incentive systems. This supports the efficient transmission of core technologies, business expertise and corporate culture, strengthens talent pipeline development and organizational capability building, and provides solid talent support for the Company's sustained high-quality development.

During the reporting period, the Company had **117** registered internal trainers (including newly appointed trainers). A total of approximately **229** training sessions were delivered throughout the year, with total training hours reaching approximately **321.7** hours, representing an increase compared with previous years.

Internal Trainer Engagement

Case

Leveraging Teachers' Day as an opportunity, Jafron organized a light appreciation initiative themed "Gratitude for Cultivation", which received wide positive feedback.



Recruitment and Development of New Internal Trainers

Case

Through referral and self-nomination mechanisms, Jafron selected 16 internal trainer candidates during the reporting period. Two rounds of empowerment training were conducted, along with two rounds of assessment and certification. Ultimately, 15 individuals successfully obtained certification.



Online Learning Platform

Jafron has independently developed the Jafron Academy online learning platform, supported by the Group Training Center and its digital infrastructure. The platform integrates online and offline training resources and is closely aligned with the development of the internal trainer system. It provides robust support for employee development, organizational capability enhancement and the dissemination of industry technologies, thereby contributing to the development of a learning organization and a talent hub within the industry.


Platform Usage (as of the end of the reporting period)



Number of users 2,482 Persons	Online learning coverage rate 97.6%	Cumulative learning hours 73,841.1 Hours
Training programs in operation 9,338 Programs	Internal and external knowledge courses retained 1,993 Courses	

Career Development

Jafron actively promotes clear and accessible career development pathways and has established the *Position and Job Grade Management Measures*, which define employee career progression routes as well as promotion and demotion criteria. Each job family is assigned defined qualification requirements, enabling a structured, transparent and diversified career development system. We've implemented a unified job grading framework, categorizing positions into three streams: managerial, technical and professional. This framework fully covers diverse career development needs, provides clear advancement pathways, and helps unlock employee potential while supporting the realization of individual career aspirations.



Key Performance



Number of Employees Undergoing Internal Transfers or Applying For Internal Positions 439 persons	Percentage of Employees Undergoing Internal Transfers or Applying For Internal Positions 17.3%
--	--

Occupational Health and Safety

Jafron regards occupational health and safety as a core foundation of its business development and adheres to the principles of "Safety First, Prevention Utmost and Holistic Control". We strictly implement work safety management standards, ensure rigorous supervision and risk control across all production processes, and provide comprehensive occupational health and safety training to foster a safe and healthy working environment. During the reporting period, Jafron was recognized as an Excellent Organization in the national "Ankang Cup" Competition and received the Excellence Award in the Zhuhai Work-Related Injury Prevention Skills Competition.



Excellence Award in Zhuhai Work-Related Injury Prevention Skills Competition

Work Safety Management System

Jafron strictly complies with the *Work Safety Law of the People's Republic of China* and the *Law of the People's Republic of China on Prevention and Control of Occupational Diseases*, among other applicable laws and regulations. We've established dedicated policies such as the *Safety Structure Management System for the Hemoperfusion Cartridge Plant* and the *Group Occupational Health Management System*. A Work Safety Committee has been established with the participation of heads of all departments, under which the EHS Department is responsible for routine safety performance assessments, hazard identification and rectification, and occupational risk management.

To ensure the achievement of safety objectives and strengthen accountability, we required all employees to sign Work Safety Responsibility Agreements during the reporting period, clearly defining safety responsibilities and key annual tasks. A corresponding safety performance evaluation mechanism is in place to regularly assess duty performance and target completion.


Occupational Health and Work Safety Targets	Achievements in 2025
Major (or above) Work Safety Incidents: 0	✓ Achieved
Occupational Disease/Poisoning Incidents: 0	✓ Achieved



Work Safety Risk Management

Risk Management Mechanism


Jafron has formulated the *Jafron Dual Prevention Mechanism Implementation Plan* and conducts regular identification, assessment and monitoring of hazard sources. We focus on key risk points and high-risk hazards that are prone to incidents, strengthening real-time monitoring and dynamic risk management. Through timely verification of monitoring data, tracking of corrective actions and implementation of risk mitigation measures, we've achieved full-process management of safety risks. This further strengthens the foundation of production safety and provides a robust safeguard for the stable operation of the Company.



Emergency Management

Jafron has developed the *Work Safety Emergency Response Plan* and established a comprehensive emergency management system with continuous optimization of response mechanisms. A dedicated emergency organizational structure has been established, comprising an Emergency Command Center led by a Commander-in-Chief responsible for overall coordination and a Deputy Commander responsible for operational coordination. Five specialized response teams have been formed, including the Emergency Rescue Team, Communication and Liaison Group, Security and Evacuation Team, Medical Aid Group and Logistics Support Team. These teams operate with clear role definitions and coordinated response mechanisms. We also conduct regular emergency drills to ensure employees are familiar with emergency procedures and to continuously enhance their capability to respond effectively to unexpected incidents.

Organizational Structure for Emergency Response



High-Rise Fire Emergency Drill at Qianfan Apartment

Case

On December 25, 2025, to draw lessons from high-rise building fire incidents, strengthen fire safety awareness across the workforce and enhance practical emergency response capabilities while improving the fire emergency preparedness system, Jafron's EHS Department, in collaboration with the Logistics Support Department, conducted a high-rise fire emergency drill at Qianfan Apartment. For the first time, the drill adopted a "no prior notice" approach, simulating a realistic nighttime fire scenario.



Identification of Potential Hazards

Jafron has established a comprehensive safety hazard identification system based on the principles of "all staff participation, end-to-end process control and full-area coverage". A multi-dimensional inspection mechanism has been implemented, combining daily, quarterly, holiday, annual and targeted special inspections. Dedicated professionals are assigned to conduct routine comprehensive safety inspections and hazard identification and remediation of production equipment and occupational health hazard control facilities, ensuring early detection and timely remediation of risks. A structured tracking ledger is maintained to monitor rectification progress. The Company continuously enhances on-site safety protection measures, optimizes operational procedures, and eliminates potential safety hazards.


During the reporting period, the Company conducted comprehensive departmental inspections, targeted safety inspections and job-level self-inspections, identifying and rectifying a total of **1,079** issues, all of which were addressed in a timely manner, achieving a **100%** rectification rate.

Case Study

On April 3, 2025, expired safety helmets were identified in a construction area and were promptly replaced as part of corrective actions.



Before Rectification



After Rectification

Safety Management Practice

Safety Management for Related Parties

Jafron has established a set of management systems, including the *Outsourced Engineering Management Policy*, the *Project Management Policy* and the *Construction Safety Management Regulations*, to strengthen the safety management of contractors and other third parties accessing the Company premises. These systems ensure that all third parties operating within the Company premises comply with established safety standards and procedures. Dedicated safety supervision teams are established, and regular safety training and assessments are conducted. The Company comprehensively manages safety risks associated with outsourced services and construction activities, ensuring safety throughout the entire project lifecycle.



Training and Culture Construction

Jafron places strong emphasis on continuously strengthening employees' safety awareness and has established a comprehensive occupational health and safety training system covering all employees. A wide range of safety awareness initiatives is actively carried out to ensure employees are equipped with essential safety knowledge and skills and meet certification requirements for their respective roles. During the reporting period, the Company organized a series of activities, including a safety hazard reporting incentive program, a company-wide EHS knowledge competition, and a fire safety skills competition. In addition, safety culture communication was further strengthened through quarterly incident alert bulletins and the "EHS Micro Classroom" section on the official WeChat platform, fostering a strong safety culture across the organization.

2025 Indicator		
Total Investment in Safety Training	Number of Safety Training Sessions	Number of Participants in Safety Training (Person-time)
RMB 68 Thousand	775 Sessions	33,178 Person-times
Total Training Duration	Average Duration of Safety Training	Coverage Rate of Safety Training
40,142 Hours	17.4 Hours	100%

EHS Awareness and Communication Campaigns



Occupational Health Protection

To further implement the *Law of the People's Republic of China on the Prevention and Control of Occupational Diseases*, Jafron has adopted a range of occupational health protection measures and fully implemented occupational disease prevention and control requirements, thereby safeguarding employees' health and lawful rights and interests.

Detection of Occupational Hazard Factors

Jafron maintains stringent end-to-end management of occupational hazard factor monitoring. Where monitoring reports identify workplace noncompliance, the Safety Management Department organizes the relevant responsible departments to develop and implement corrective actions. For roles with severe noncompliance, production is suspended immediately, and operations may only resume once remediation has been completed and compliance has been verified. In addition, the Company engages qualified occupational health technical service providers on an annual basis to conduct occupational hazard factor testing, and completes at least one comprehensive occupational disease hazard status assessment every three years. Through institutionalized and routine monitoring measures, the Company continuously strengthens occupational health risk prevention and control and effectively safeguards employees' occupational health rights and interests.


During the Reporting Period, the Company's occupational disease hazard factor detection rate was **100%**, and the monitoring compliance rate for occupational disease hazard factors was **100%**.



Occupational Hazard Factor Detection Report

Fire Safety Skills Competition

On the afternoon of September 12, 2025, Jafron's EHS Department organized a fire safety skills competition in the northern area of Jianfan Industrial Park, continuously enhancing employees' emergency response capabilities and teamwork skills.



Occupational Hazard Protection Measures

Jafron has established the *Personal Protective Equipment Management Policy* and the *Static Electricity Protection Safety Management Policy*, and provides employees with adequate personal protective equipment (PPE) that meets national standards, including protective footwear, gloves, and masks. A standardized storage, distribution, and management mechanism has been implemented to ensure PPE compliance and usability. Risk communication is reinforced through on-site postings and warning signage. Through integrated measures covering individual protection, PPE management, and risk notification, the Company has established a comprehensive occupational hazard protection system, effectively reducing occupational health risks in the workplace and safeguarding employee health and safety.



PPE

Hazard Notification Cards

Occupational Health Checkups

Jafron places strong emphasis on occupational health management and has established the *Employee Health Management Policy*, implementing full lifecycle occupational health management requirements. Occupational health examinations are conducted for employees prior to employment (including job transfers), during employment and upon departure. For employees newly hired or transferred into occupational hazard-related positions, the Company promptly issues the *Written Notification of Occupational Hazards*. Employees with occupational contraindications are reassigned in accordance with applicable regulations. Occupational health records are established and continuously improved to ensure closed-loop management across the entire occupational health process, effectively safeguarding employees' occupational health rights and interests. During the Reporting Period, the coverage rate of employee health checkups reached 100%, and 0 new occupational disease cases occurred in the Company.



Social Contribution

Guided by its public welfare philosophy of "caring for life and prioritizing health", Jafron adheres to the principle of "technology for good" and leverages its strengths as a medical technology enterprise to fulfill social responsibility through public welfare initiatives, contributing to human health and broader social development.

Continuing Guangcai Program

As a high-tech medical enterprise specializing in blood purification, Jafron actively responds to national strategic priorities while pursuing its own development. We fully leverage the important role of the Guangcai Program in demonstrating the strengths of socialism with Chinese characteristics, promoting coordinated urban and rural development, and advancing the healthy business development and healthy entrepreneur growth. By improving public well-being and contributing to national strength and rejuvenation, we continue to write a new chapter for the Guangcai Program and contribute to Chinese modernization.

In October 2025, at the 2025 World Guangdong Entrepreneurs Convention, Jafron received the "Guangdong Guangcai Program Contribution Award" in recognition of its long-term commitment to the Guangcai Program and its outstanding contributions to the development of primary healthcare institutions.



Jafron Chairman and President Dong Fan Re-elected as Executive Director of China Society for Promotion of the Guangcai Program

On November 26, 2025, the Seventh National Members' Congress of the China Society for Promotion of the Guangcai Program was held in Beijing. Wang Huning, Member of the Standing Committee of the Political Bureau of the CPC Central Committee and Chairman of the National Committee of the Chinese People's Political Consultative Conference, met with all delegates attending the conference. During the meeting, the leadership of the Seventh Council was elected, and Dong Fan was successfully re-elected as an Executive Director.

Guangcai Program in Yangchun – Jafron Awarded "Outstanding Private Enterprise Contributor"

On December 23, 2025, Jafron donated RMB 3 million to Yangjiang City, Guangdong Province, to support the construction of a rural revitalization workshop in Qigu Village, Tanshui Town, Yangchun City. In parallel, the Company implemented a photovoltaic rooftop project for a basketball court at a cultural and sports plaza. This "industry + solar energy + culture" integrated model enhances rural development by combining industrial upgrading, cultural continuity, collective income growth and low-carbon development into a comprehensive public welfare benchmark program.

Social Public Welfare Governance

Jafron actively aligns with national strategic priorities, integrating its development with key national initiatives such as the Healthy China Strategy, Rural Revitalization Strategy, and Regional Coordinated Development Strategy. The Company continues to innovate its social responsibility practices, building a framework centered on "technology empowerment + targeted support + ecosystem co-creation", and has established a structured and sustainable CSR governance system with multi-dimensional implementation pathways.

A dedicated CSR department has been established to coordinate the full lifecycle management of public welfare initiatives, systematically manage CSR data, and support integrated brand communication. In 2025, the team implemented more than 10 major public welfare donation programs, demonstrating the Company's commitment to social responsibility through concrete actions.

During the Reporting Period, the Company invested a total of RMB 44.5931 million in public welfare.

Medical Support to Safeguard Health

Guided by professional expertise and a commitment to social well-being, Jafron gives back to society through tangible action. As a domestic enterprise specializing in blood purification, the Company aligns closely with the "Healthy China" strategy, which emphasizes strengthening primary healthcare service capacity and safeguarding the foundational level of public health. Leveraging its core technological capabilities, the Company embeds technology accessibility throughout the entire process of grassroots medical assistance.

In patient access and healthcare system coordination, the Company promotes advanced medical devices and solutions in regions with unmet healthcare needs, thereby enhancing primary-level public health capacity. It also supplies disposable hemoperfusion cartridges to grassroots medical institutions at inclusive pricing, accelerating deployment in county-level hospitals, reducing the cost of healthcare access, and improving equity and accessibility of medical resources.

Supporting Healthcare Development in Bijie

Case

On June 20, 2025, at the industry-focused coordinated support meeting of the United Front Work system held in Zhijin County, Bijie City, Jafron donated medical supplies with a total value of approximately RMB 1 million to Zhijin, Dafang and Hezhang counties. The donation was closely aligned with the needs of primary healthcare institutions and supported the advancement of local healthcare services.



Supporting Yichang's "Dialysis Patients Returning Home Project"

Case

In August 2025, in response to the "Dialysis Patients Returning Home Project" coordinated by the Yichang Municipal Health Commission, Jafron collaborated with multiple stakeholders to meet the donation needs of 35 township health center dialysis units across nine counties in Yichang. The Company urgently allocated and donated hemodialysis powder and concentrate products with a market value of over RMB 990,000. The first batch of donated materials has been successfully delivered and is being progressively put into use, supporting grassroots dialysis centers through a critical development phase.



Precision Manufacturing Inclusive Healthcare Initiative

Case

In alignment with national medical insurance reform priorities of cost containment and quality improvement, Jafron proactively adjusted the pricing of disposal hemoperfusion cartridges. Through the "Precision Manufacturing Inclusive Healthcare Initiative", the Company reduced the price of domestically produced medical devices, promoted the DX-10 blood purification machine at inclusive pricing to primary healthcare markets, and provided an integrated "equipment + consumables + training + service" end-to-end solution. This is supported by more than 500 technical training sessions annually and an after-sales service system backed by a professional team of over 1,000 personnel, accelerating equipment deployment in county-level hospitals and enhancing critical care capacity at the primary level. To date, these initiatives have reached multiple grassroots medical institutions nationwide, effectively addressing the "last mile" challenge in healthcare equity and demonstrating the responsibility of a domestic medical device enterprise.

In academic and standard-setting engagement, Jafron continues to disseminate professional knowledge through publications and standards development. By leveraging technological innovation to support inclusive healthcare practices, we contribute to the standardization of blood purification diagnosis and treatment at the primary level. To date, Jafron products and technologies have been cited in over 1,000 academic papers, including more than 300 English-language publications, helping to improve the quality of grassroots healthcare services.

Meanwhile, the Company addresses the needs of specific vulnerable populations through targeted support initiatives. The Company participated in the "Her Health" Care Program for underprivileged women in Zhuhai, Guangdong Province, providing insurance coverage for seven major female cancers ("Seven Cancers" insurance), precisely filling gaps in health protection for disadvantaged groups and aligning with the national policy direction of strengthening basic social welfare safeguards. In 2023, the Company donated RMB 2 million to support the "Caring for Dialysis Patients" program for the prevention and care of dialysis-related complications among uremia patients, helping low-income uremia patients alleviate financial burdens. The program has been implemented continuously for 3 years, and as of 2025, a total of 3,485 service instances have been provided.



Contribute to Rural Revitalization

Jafron closely aligns with the strategic priorities of the Central Committee of the Communist Party of China and the State Council to comprehensively advance rural revitalization. Leveraging its core capabilities, the Company deepens its medical assistance efforts and actively explores long-term mechanisms to support rural revitalization. Focusing on key development challenges in county-level regions, the Company is shifting its support model from one-off donations to "capacity-building" empowerment, promoting coordinated improvements in rural industry, livelihoods, and culture.

In 2025, the Company advanced rural revitalization initiatives across multiple dimensions, including industrial support, cultural revitalization, ecological development and healthcare improvement. During the 2025 "6-30" Rural Revitalization Campaign in Zhuhai, the Company pledged RMB 15 million in donations, actively participating in rural revitalization efforts and fully supporting paired-assistance and cooperation regions in consolidating and expanding poverty alleviation outcomes, injecting strong momentum into comprehensive rural revitalization.

Charitable Donation to Safeguard Rural Health and Well-being

Case 

On October 17, 2025, through the Jafron Medical Foundation, Jafron donated RMB 100,000 for the renovation of the Meizhou Village clinic in Xiaoxishi Township, Shaoyang County, Hunan Province. At the same time, the Company donated foam-based hand sanitizer and other supplies tailored to primary healthcare settings, strengthening infection prevention capacity at the clinic, supporting rural primary healthcare infrastructure, and enabling residents to access safe and high-quality medical services within their communities.



Six Consecutive Years of Support for the "Light of Gesang Flower" Cataract Restoration Public Welfare Initiative

Case 

On May 8, 2025, Jafron donated RMB 500,000 to the Zhuhai Red Cross Society. From 2020 to 2025, the Company has continuously supported the "Light of Gesang Flower" Cataract Restoration Public Welfare Initiative in Tibet for six consecutive years. The program provides free cataract surgeries for Tibetan patients suffering from eye diseases and helps local physicians master advanced ophthalmic treatment technologies, contributing to the development of a sustainable, locally rooted medical workforce.



Appendix

Indexes

Shenzhen Stock Exchange Self-Regulatory Guidelines No. 17 for Companies Listed on Shenzhen Stock Exchange—Sustainability Report (For Trial Implementation)

Disclosure Requirements	Corresponding Sections of This Report
Response to Climate Change	Advancing Green Transformation to Enable Sustainable Healthcare - Response to Climate Change
Pollutant Emissions	Advancing Green Transformation to Enable Sustainable Healthcare - Environmental Compliance Management
Waste Disposal	Advancing Green Transformation to Enable Sustainable Healthcare - Environmental Compliance Management
Ecosystem and Biodiversity Protection	Advancing Green Transformation to Enable Sustainable Healthcare - Ecosystem and Biodiversity Protection
Environmental Compliance Management	Advancing Green Transformation to Enable Sustainable Healthcare - Environmental Compliance Management
Energy Utilization	Advancing Green Transformation to Enable Sustainable Healthcare - Resource Utilization
Water Resource Utilization	Advancing Green Transformation to Enable Sustainable Healthcare - Resource Utilization
Circular Economy	Advancing Green Transformation to Enable Sustainable Healthcare - Resource Utilization
Rural Revitalization	Building a Harmonious Workplace through People-Oriented Development - Social Contribution
Social Contribution	Building a Harmonious Workplace through People-Oriented Development - Social Contribution
Innovation-driven Development	Driving Industry Transformation through Innovation and Collaboration - Innovation-driven Development
Science and Technology Ethics	Driving Industry Transformation through Innovation and Collaboration - Innovation-driven Development
Supply Chain Security	Driving Industry Transformation through Innovation and Collaboration - Responsible Supply Chain
Equal Treatment of Small and Medium-Sized Enterprises	The Company has no accounts payable balances exceeding RMB 30 billion or accounting for over 50% of total assets, nor has it publicly disclosed information regarding overdue payments to small and medium-sized enterprises through the National Enterprise Credit Information Publicity System. Therefore, this topic was not identified as a material topic during the Reporting Period.
Safety and Quality of Products and Services	Promoting Industrial Upgrading through Lean Innovation – Product Safety and Quality Promoting Industrial Upgrading through Lean Innovation – Customer Service
Data Security and Customer Privacy Protection	Driving Industry Transformation through Innovation and Collaboration - Information Security and Data Protection
Employees	Building a Harmonious Workplace through People-Oriented Development - Protection of Employees' Rights and Interests Building a Harmonious Workplace through People-Oriented Development - Training and Development Building a Harmonious Workplace through People-Oriented Development - Occupational Health and Safety
Due Diligence	Consolidating the Foundation for Sustainable Development through Steadfast Governance - Compliant Operation and Risk Management
Communications with Stakeholders	Sustainable Development Governance - Communications with Stakeholders

Disclosure Requirements	Corresponding Sections of This Report
Anti-Commercial Bribery and Anti-Corruption	Consolidating the Foundation for Sustainable Development through Steadfast Governance - Business Ethics
Anti-Unfair Competition	Consolidating the Foundation for Sustainable Development through Steadfast Governance - Business Ethics
Self-Disclosure Topics:	
Access to Healthcare	Annual Thematic Initiative: "Love Life, Love Life More" – 919 Uremia Awareness Day Driving Industry Transformation through Innovation and Collaboration - Innovation-driven Development Building a Harmonious Workplace through People-Oriented Development - Social Contribution
Occupational Health and Safety	Building a Harmonious Workplace through People-Oriented Development - Occupational Health and Safety

Key Performance Form

Economic Performance				
Indicator Name	Unit	2024	2025	
Operating Revenue	RMB 100 million	26.77	20.12	
Net Profit Attributable to Owners of the Parent Company	RMB 100 million	8.20	5.33	
Total Assets	RMB 100 million	53.83	54.09	
Earnings per Share	Yuan/Share	1.02	0.69	
Total Taxes	RMB 100 million	4.70	4.02	

Governance Performance				
Indicator Name	Unit	2024	2025	
Training on Laws and Regulations (Session)	Session	4	4	
Signing Rate of Integrity and Other Related Business Ethics Agreements	/	100%	100%	
Anti-corruption and Anti-bribery Incidents Reported	Case	0	0	
Number of the Management Participating in Training on Anti-commercial Bribery and Anti-Corruption	Person	66	42	
Total Duration of Training on Anti-commercial Bribery and Anti-Corruption for the Management	Hour	528	115	
Number of Employees Participating in Training on Anti-commercial Bribery and Anti-Corruption	Person	292	1,047	
Total Duration of Training on Anti-commercial Bribery and Anti-Corruption for Employees	Hour	2,336	2,087	

Environmental Performance				
Response to Climate Change				
Indicator Name	Unit	2024	2025	
Total GHG Emissions ¹	tCO ₂ e	19,309.47	13,974.11	
Direct GHG Emissions (Scope 1) ¹	tCO ₂ e	8,644.93	5,595.53	
Indirect GHG Emissions (Scope 2) ¹	tCO ₂ e	10,664.54	8,378.58	
Natural Gas	10,000 m ³	399.823	258.79	
Total Purchased Electricity	kWh	27,564,090	20,728,790	
Photovoltaic Power Generation ²	kWh	1,725,780	2,082,300	
Total Energy Consumption ³	tce	8,397.60	5,908.964	

Note 1: Reported GHG emissions include Scope 1 (direct) and Scope 2 (indirect) emissions, which are calculated in accordance with the *GHG Emissions Accounting and Reporting Guidelines for Industrial Enterprises (Other Sectors)*.
 Note 2: Total energy consumption includes natural gas, purchased electricity and solar-generated electricity. Natural gas emissions are calculated based on a conversion factor of 1 m³ of natural gas equivalent to 1.20 kg of standard coal by energy content.

Environmental Compliance Management				
Indicator Name	Unit	2024	2025	
Total Environmental Investment	RMB 10,000	8,541.02	228.80	
Number of Major Administrative Penalty Cases imposed by Ecological and Environmental Authorities due to Environmental Incidents	Case	0	0	
Amount of Major Administrative Penalties Imposed by Ecological Environment and Other Relevant Authorities for Environmental Incidents	RMB 10,000	0	0	
Training on Environmental Protection	Session	12	10	
Number of Participants in Training on Environmental Protection	Person-times	105	80	
Duration of Training on Environmental Protection	Hour	97	60	

Pollutant Emissions			
Indicator Name	Unit	2024	2025
Waste Gas Emission	Ton	5,333.65	3,467.83
Nitrogen oxide (NOX)	Ton	7.85	2.42
Sulfur Dioxide	Ton	0.19	0.24
Volatile Organic Compounds (VOC)	Ton	3.78	2.67
Particulate Matter (PM)	Ton	0.17	0.10
Wastewater Discharges	Ton	141,383	79,779
Chemical Oxygen Demand (COD)	Ton	1.829	0.775
Ammonia Nitrogen (NH3-N)	Ton	0.011	0.004
Total Phosphorus (Calculated at P)	Ton	0.004	0.348

Waste Disposal			
Indicator Name	Unit	2024	2025
Volume of Non-hazardous Waste Generated	Ton	661.64	377.47
Disposal Volume of Non-hazardous Waste	Ton	373.08	154.24
Volume of Hazardous Waste Generated	Ton	121.82	145.20
Disposal Volume of Hazardous Waste	Ton	121.82	145.20
Total Recycled Waste	Ton	288.56	144.56
Waste Disposal Compliance Rate	/	100%	100%
Waste Oil (HW08 Category)	Ton	/	0.72
Waste Organic Solvents (HW06 Category)	Ton	106.54	124.98
Waste Activated Carbon (Hw49)	Ton	13.02	15.47
Laboratory Waste (HW49 Category)	Ton	0.67	1.27
Waste Containers (HW49 Category)	Ton	1.6	0.67
Sludge	Ton	373.08	232.91

Water Resource Utilization			
Indicator Name	Unit	2024	2025
Total Water Consumption	Ton	753,795	538,030
Total Freshwater Withdrawal	Ton	705,038	483,152
Total Water Circulation and Reuse	Ton	48,757	54,878

Material Utilization			
Indicator Name	Unit	2024	2025
Total Use of Packaging Materials	Ton	8,432.32	5,114.62
Paper Packaging Materials	Ton	8,158.35	4,947.75
Plastic Packaging Materials	Ton	273.97	166.87
Quantity of Packaging Materials Recycled	Ton	/	28.84

Social Performance

Innovation-driven Development				
Indicator Name	Unit	2023	2024	2025
Investment in R&D	RMB 10,000	24,537.87	24,009.32	19,844.53
Percentage of R&D Investment in Main Business Revenue	/	12.79%	8.97%	9.89%
Total Number of R&D Team Members	Person	544	486	405
Ratio of R&D Personnel to Total Employees	/	22.59%	17.38%	17.60%
Number of Patent Applications	Item	50	53	50
Granted Patents (Valid)	Item	37	27	45
Number of Granted Invention Patents	Item	22	17	20
Number of Granted Utility Model Patents	Item	15	8	17
Number of Granted Design Patents	Item	0	2	8
Total Number of Trademarks	Item	239	243	246
Specialized and Sophisticated Enterprise that Produces Novel and Unique Products	Entity	2	2	1
National High-tech Enterprise	Entity	4	4	3
National Enterprise Technology Center	Entity	1	1	1

Product Safety and Service Quality				
Indicator Name	Unit	2023	2024	2025
First Pass Yield	/	100%	100%	100%
Number of Internal Quality Audits in a year	Session	2	2	2
Number of Sampling Inspections by Third-Party Organizations	Time	4	6	4
Number of Product Recalls	Piece	0	0	0
Including: Number of Products Withdrawn or Recalled due to Health and Safety Concerns	Piece	0	0	0
Amount Involved in Major Liability Accidents Related to the Safety and Quality of Products or Services	RMB 10,000	0	0	0
Number of Participants in Quality Training	Person-times	/	4,953	4,197
Total Hours of Quality Training	Hour	/	24,672	8,188
Sessions of Quality Training	Session	/	20	18
Number of Customers Participating in the Survey	Person	517	392	480
Number of Valid Copies of Customer Satisfaction Questionnaires Issued	Copy	517	481	574
Customer Satisfaction / Total Satisfaction Score ¹	/	98.99%	99.04%	97.14%
Customer Complaint Resolution Rate	/	/	100%	100%

Note 1: The overall customer satisfaction is calculated by averaging the following satisfaction measures—Adsorbent category: 98.8%, Equipment category: 97.1%, Tubing category: 97.2%, Plasma Separator/Hemodialyzer category: 92.6%, Bandage category: 100%.

Supply Chain Security				
Indicator Name	Unit	2023	2024	2025
Total Number of Suppliers	Supplier	400	459	503
Signing Rate of Integrity Agreement by Suppliers	/	22%	19%	36%
Number of Incidents with Major Risk and Impact in the Supply Chain	Case	0	0	0

Data Security and Customer Privacy Protection				
Indicator Name	Unit	2023	2024	2025
Number of Incidents Involving Leakage of Customer Information	RMB 10,000	0	0	0
Verified Complaints Involving Infringement of Customer Privacy and Loss of Customer Data	Case	0	0	0
Total Number of Confirmed Leaks, Thefts, or Losses of Customer Data	Case	0	0	0
Number of Training Sessions on Data Security/Customer Privacy Protection	Session	8	9	2
Coverage Rate of Training on Data Security/Customer Privacy Protection	/	100%	100%	100%
Per Capita Training Hours for Training on Data Security/Customer Privacy Protection	Hour	8	18	2

Social Contribution				
Indicator Name	Unit	2023	2024	2025
Public Welfare Investments ¹	RMB 10,000	2,613.96	3,830.22	4,459.31

Note 1: The amount includes both monetary and in-kind donations, with in-kind donations calculated at fair value.

Employee Training and Development				
Indicator Name	Unit	2023	2024	2025
Investment in Employee Training	RMB 10,000	34.45	34.23	35.63
Number of Employee Training Sessions	Sessions	2,026	3,540	1,720
Total Number of Persons Trained (Person) ¹	Person	2,643	3,042	2,487
Total Number of Persons Trained (Person-time)	Person-times	26,562	61,448	48,377
Total Training Duration	Hour	75,933.39	92,872.26	73,841.10
Average Training Duration per Employee per Year	Hour/Person	28.73	30.53	30.93
Coverage Rate of Employee Training (Training Ratio of Employee)	/	100%	100%	98%

Note 1: Total Number of Persons Trained includes former employees.

Labor's Rights and Interests				
Indicator Name	Unit	2023	2024	2025
Signing Rate of Employment Contract	/	100%	100%	100%
Labor Dispatch Workers	Person	0	0	0
Part-time Employees	Person	0	0	0
Total Number of Employees	Person	2,408	2,797	2,301
Number of Employees with Disabilities	Person	0	8	6
Number of Employees of Minority Nationalities	Person	41	120	85
Percentage of Employees of Minority Nationalities	/	2%	4%	4%
Including: Number of Employees by Gender				
Female	Person	990	1,154	972
Male	Person	1,418	1,643	1,329
Including: Number of Employees by Age				
Under 30 (exclusive) Years Old	Person	729	886	622
30 (inclusive) to 40 (exclusive) Years Old	Person	1,384	1,574	1,285
40 (inclusive) to 50 (exclusive) Years Old	Person	255	302	354
50 years old or above	Person	40	35	40
Including: Number of Employees by Education Background				
Below bachelor's degree	Person	1,063	1,298	958
Bachelor's Degree	Person	1,140	1,251	1,086
Master's Degree	Person	197	242	250
Doctoral Degree	Person	8	6	7
Including: Number of Employees by Region				
Chinese Mainland	Person	2,406	2,794	2,298
Hong Kong, Macao and Taiwan Regions	Person	1	2	2
Overseas	Person	1	1	1
Number of New Employees	Person	296	1,248	295
Including: Number of New Employees by Gender				
Female	Person	105	487	114

Labor's Rights and Interests				
Indicator Name	Unit	2023	2024	2025
Male	Person	191	761	181
Including: Number of New Employees by Age				
Under 30 (exclusive) Years Old	Person	157	653	202
30 (inclusive) to 40 (exclusive) Years Old	Person	118	521	80
40 (inclusive) to 50 (exclusive) Years Old	Person	19	71	12
50 years old or above	Person	2	3	1
Including: Number of New Employees by Region				
Chinese Mainland	Person	296	1,245	295
Hong Kong, Macao and Taiwan Regions	Person	0	2	0
Overseas	Person	0	1	0
Proportion of Female Employees in Management	/	34%	30%	24%
Number of Employees on Maternity Leave	Person	100	99	91
Return Rate of Employees on Maternity Leave	/	100%	100%	100%
Number of Employees on Parental Leave	Person	65	48	48
Return Rate of Employees on Parental Leave	/	100%	100%	100%
Coverage Rate of Social Insurance	/	100%	100%	100%
Proportion of Employees Receiving Regular Performance and Career Development Assessments	/	100%	100%	100%
Number of Employees Resigned	Person	880	858	792
Number of Employees Resigned ¹	/	26.80%	23.50%	25.60%

Note 1: Total Employee Turnover Rate = total Number of Employees Who Left during the Reporting Year / (Total Number of Employees Who Left during the Reporting Year + Total Number of Employees on the Payroll at the End of the Reporting Year)

Occupational Health and Safety				
Indicator Name	Unit	2023	2024	2025
Number of Work Safety Accidents	Case	0	0	0
Number of Work-Related Deaths	Person	0	0	0
Total Number of Work-Related Injuries	Person	/	3	1
Working Day Lost due to Work-related Injury	Working Days	/	48	67
Identification and Rectification Rate of Potential Hazards	/	100%	100%	100%
Number of Security Emergency Drills	Sessions	91	69	143
Investment in Work Safety ¹	RMB 10,000	/	433.65	261.02
Total Investment in Safety Training ¹	RMB 10,000	/	6.6	6.8
Number of Safety Training Sessions	Session	64	110	775
Number of Participants in Safety Training (Person-time)	Person-times	11,581	12,779	33,178
Total Training Duration	Hour	13,042	13,430	40,142
Coverage Rate of Safety Training	/	/	100%	100%
Coverage Rate of Training on Safety Risk Prevention	/	/	100%	100%
Permit Holding Rate for Personnel Engaged in Special Operations	/	100%	100%	100%
Investment in Work-Related Injury Insurance	RMB 10,000	62.62	97.25	135.07
Coverage Rate of Work-Related Injury Insurance	/	100%	100%	100%
Coverage Rate of Health Checkups among Employees	/	100%	100%	100%
Detection Rate of Occupational Hazard Factors	/	100%	100%	100%
Qualification Rate in Detection of Occupational Hazard Factors	/	100%	100%	100%
Number of New Occupational Diseases	Case	0	0	0

Note 1: The investment in work safety and total investment in safety training throughout 2024 are estimated amounts.

Feedback Form

Dear Readers,

Thank you for reading this report. We highly value and look forward to hearing your feedback on this report. Your opinions and suggestions are an important driving force for us to continuously improve our ESG information disclosure quality and deepen our ESG management and practices. We sincerely welcome and thank you for your engagement and support!

1. Your overall assessment of Jafron's ESG management and practices:

Very Good Good Average Below Average Poor

2. Your overall assessment of this report:

Very Good Good Average Below Average Poor

3. How do you think Jafron has performed in terms of communications with stakeholders?

Very Good Good Average Below Average Poor

4. How do you think Jafron has performed in terms of corporate governance?

Very Good Good Average Below Average Poor

5. How do you think Jafron has performed in terms of environment protection, resource management and response to climate change?

Very Good Good Average Below Average Poor

6. How do you think Jafron has performed in terms of product management?

Very Good Good Average Below Average Poor

7. How do you think Jafron has performed in terms of supply chain safety?

Very Good Good Average Below Average Poor

8. How do you think Jafron has performed in terms of the protection of employees' rights and interests and the management of occupational health?

Very Good Good Average Below Average Poor

9. What are your opinions and suggestions on Jafron's ESG performance and this report?

You can contact us at:

Website: www.jafron.com

Tel.: 0756-3619693

Email: ir@jafron.com

Address: 98 Keji 6th Road, Zhuhai National High-tech Industrial Development Zone, Zhuhai City, Guangdong, China